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ABSTRACT
In the present study, human heterohybridoma techniques 
were employed in an endeavour to produce stable human 
thyroid cell lines that would express autoantigens.
Human thyrocytes obtained from a Graves patient were fused 
with second and third generation human X mouse 
heterohybridomas according to standard hybridoma 
technologies. The resultant hybridomas were selected by 
their growth in HAT medium. 70 stable cell lines (termed 
HTH) were established, expanded, cry©preserved and 
characterised.
Several thyroglobulin secreting fibroblastic lines were 
initially identified by means of a specific thyroglobulin 
ELISA utilising murine monoclonals. These lines however, 
proved unstable and were eventually lost.
Screening of the cellular supernatants for human 
immunoglobulin revealed the presence of 5 immortalised 
thyroid infiltrating lymphocytes. Immune-histochemical 
staining techniques failed to identify their specificity.
Karyotypic analysis of selected HTH lines confirmed their 
human origin.
SDS-PAGE analysis of the cellular proteins suggested that 
the HTH lines obtained had two basic phenotypes.These were 
fibroblastic and lymphocytic. Following extensive screening, 
none of the novel HTH lines were found to express the common 
thyroid antigens. They were therefore deemed unsuitable as 
thyroid cell "models".
In summary this study has demonstrated the potential
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usefulness of human heterohybridoma technology in producing 
long term stable human cell lines.
Two assays were developed for the detect ion of TSH 
receptor antibodies (TRAB). Both ELISA systems depended on 
the immobilisation of partially purified porcine TSH receptor 
to microtitre plates. The purification was achieved by using 
lectin and TSH affinity chromatography.
The competitive ELISA depended on the direct inhibition of 
enzyme labelled TSH by sample autoantibodies. This assay 
failed to function in a serum matrix and was therefore 
terminated in favour of an indirect approach.
The indirect ELISA depended on TSH receptor autoantibodies 
binding specifically to the TSH receptor. Bound antibodies 
were detected by the means of an enzyme labelled second 
antibody.
Validation of the proposed ELISA against the existing 
radioreceptor assay resulted in a correlation of 0.84. The 
precision and recovery of the ELISA were good and no 
significant cross reactivity was observed with other common 
autoantibodies.
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ABBREVIATIONS.
ABTS 2, 2' -Azino-di(3-ethyl-benzothiazoline
-6-sulphonic acid)+
AITD Autoimmune thyroid disease
8AZA 8-Aza-guanine
B.C.A Bicinchoninic acid
B.S.A Bovine serum albumin
CV Coefficient of variation
cAMP Cyclic adenosine 5'-triphosphate
DEAE Dimethylaminoethyl anion exchange column
DMSO Dimethyl sulphoxide
EBV Epstein-Barr virus
ED TA Ethylenediaminetetraacetic acid
ELISA Enzyme linked immunosorbent assay
ECS Foetal calf serum
FITC Fluorescein isothyocynate
FRTL-5 Ficher rat thyroid cell line
GOD Glucose oxidase
HAT Hypoxanthine, aminopterin, thymidine
HLA Human leukocyte antigen
HRPO Horse radish peroxidase
HFP2A Human fusion partner (second generation)
HFP3 Human fusion partner (third generation)
HT Hypoxanthine, thymidine selection
HTH Human thyroid derived hybri.doma lines
ICA Islet cell antigen
IgG Immunoglobulin G
IgM Immunoglobulin M
IRMA Immunoradiometric assay
LATS Long acting thyroid stimulator
NS-1 Murine cell fusion partner
NSB Non specific binding
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PBSGT Phosphate buffered saline containing gelatine & 
Tween-20
PEG Polyethylene glycol
RIA Radioimmunoassay
SP2 Murine cell fusion partner
SD Standard deviation
SDS Sodium dodecyl sulphate
SEM Standard error of the means
SV40 Simian Virus 40
T 3
L-triiodothyronine
T 4 L-thyroxine
TBT Tris buffered saline
TMB 3,3'5,5'-Tetramethylbenzidine
TNB Tris buffered saline containing B.S.A
Tg Thyroglobulin
TPO Thyroid peroxidase
TRAB TSH receptor autoantibody
TSH Thyroid stimulating hormone (thyrotropin)
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GENERAL INTRODUCTION.
5
1.1.1 The Thyroid And It/s Role In Auto Immunity.
Thyroid disease is one of the most common endocrinological 
disorders in man. It encompasses a diverse range of 
conditions which are generally classified by their clinical 
manifestations into two groups ; hyperthyroidism and 
hypothyroidism.
For the purpose of this study a literature review 
concentrating on autoimmune thyroid diseases, in particular 
Grave's disease and Hashimoto's thyroiditis is given below;
Hyperthy roidi sm
Hyperthyroidism (thyrotoxicosis) is a syndrome of metabolic 
and pathologic findings resulting from the action of 
excessive concentrations of circulating thyroid hormones on 
peripheral tissues. Typically the increase in thyroid 
hormone is reflected by low levels of circulating 
thyrotropin (TSH).
Thyrotoxicosis may result from a number of conditions 
(summarised in Table 1.1), but by far the most common 
disorder is Graves disease (other oponyms include; Basedow's 
Parry's and Flajani's disease), accounting for 70 to 80% of 
all cases (Allen & Braverman, 1987).
It is characterised by a diffusely hyperplastic goiter 
often associated with characteristic eye signs, prétibial 
dermopathy and other extrathyroidal manifestations (reviewed 
by Geffner & Hershman, 1979). It usually occurs in young 
adults, typically between 20 and 50 years of age, with a 
predisposition to women.
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The autoimmune nature of the disorder is characterised by 
the presence of TSH receptor antibodies, both stimulatory 
and inhibitory which are usually determined by cell bioassay 
(Kohn et al, 1986), or by a commercial porcine receptor 
assay (for example Henning Berlin).
The presence of other thyroid specific autoantibodies is 
common, including throglobulin antibody, thyroid peroxidase 
antibody, collagen stimulating antibody and adenylate- 
cyclase stimulating antibody (Williams & Goodburn, 1983).
Thyroid associated opthalmopathy is closely related to 
Graves disease and is characterised by periorbital oedema, 
exopthalmos and eye muscle disfunction. Cross reactive 
autoantibodies to a common epitope present within the eye 
and the thyroid are generally believed to be the cause 
(reviewed by Perros & Kendall-*Taylor, 1989) .
The actual etiology of Graves autoimmune disease is still 
not fully understood, but inheritance, stress and 
environmental factors all play a role. These will be 
discussed in further detail in later sections.
Hypothyroidism.
Hypothyroidism is far less prevalent than hyperthyroidism 
and has many etiologies (Table 1.2). The characteristic 
clinical features such as weight gain, sensitivity to cold, 
slow speech, apathy, general myxoedema, slow reflex and 
pulse (reviewed by Williams & Goodburn, 1983), depend on the 
degree of thyroid hormone deficiency.
The causes of hyperthyroidism are generally classified 
into three groups ; primary (thyroprivic) , secondary
7
(pituitary) and tertiary (hypothalmic).
Primary hypothyroidism is by far the most common, 
accounting for nearly 95% of all diagnosed cases. The 
disorder originates from the thyroid gland's inability to 
produce enough hormones (T3, T4) .
Secondary and tertiary hypothyroidism are a consequence of 
other glands not secreting adequate levels of thyroid 
releasing hormone (TRH) and thyrotropin (TSH).
Thyroprivic hypothyroidism occurs most frequently in 
middle age and has a sex incidence ratio of about 6:1 (F:M). 
Nearly 75% of the cases are caused by autoimmune thyroiditis 
(Hashimoto's and chronic lymphocytic thyroiditis). The 
remaining cases are mainly due to Graves patients after 
treatment (Amino, 1988) .
Hashimoto's thyroiditis is a chronic autoimmune disease 
which shows the characteristic symptoms of hypothyroidism 
with a diffusely enlarged horseshoe shaped gland. 
Histologically fibrosis, loss of thyroid architecture and 
lymphocytic infiltration are observed.
The presence of very high titer microsomal and 
thyroglobulin autoantibodies is indicative of the disorder 
and thus is used as a diagnostic marker. In addition, low 
titer TSH receptor and other thyroid specific autoantibodies 
can be detected in many of these patients.
The actual etiology behind this destructive autoimmune 
disease is not yet understood, but genetic and environmental 
factors play a role in it's pathogenesis.
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TABLE JLJL CLASSIFICATION fiE HYPERTHYROIPI.SIL,
1) Toxic diffuse goiter (Graves, Basedow's, or Parry's 
disease: exophthalmic goiter).
2) Toxic nodular goiter (Plummer's disease)
A. Toxic uninodular goiter
B. Toxic multinodular goiter.
3) Toxic goiter with functioning nodules and parenchyma 
(Marine-Lenhart syndrome).
4) Toxic goiter with chronic thyroiditis (Hashitoxicosis).
5) Subacute thyroiditis.
6) Malignant goiter.
7) Struma ovarii.
8) Paraneoplastic syndromes;
A. Pituitary tumours
B. Trophoblastic tumours
C. Miscellaneous tumours.
9) Exogenous thyroid administration (thyrotoxicosis factitia 
and medicam entosa).
10) Iodine induced hyperthyroidism (Coindet's disease, Jod- 
Basedow).
11) Neonatctl thyrotoxicosis.
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TABLE 1^ 2. CAUSES QSL HYPOTHYROIDISM
1) Congenital anomalies;
A. Agenesis and maldevelopment
B. Ectopic thyroid
C. Dyshormonogenesis
D . Congenital exposure to iodide or anti thyroid 
compounds.
2) Autoimmune thyroid disease;
A. Autoimmune thyroiditis (Hashimoto's disease)
B. End stage Graves disease.
3) Iatrogenic thyroiditis.
4) Infiltrative disease of the thyroid.
5) Endemic hypothyroidism.
6) Disorders of the thyroid hormone activity
A. Peripheral resistance to thyroid hormones
B. Anti thyroid hormone antibodies.
C. Impaired conversion T3 to T4.
7) Hypothalmic-pituitary hypothyroidism;
A. Depressed hypothalmic function
B. Panhypopituitarism
C. Selective TSH deficiency
D. Anorexia nervosa.
10
1.1.2 The Immunogenetics Of Autoimmune Thyroid Disease.,.
The autoimmune thyroid disorders (Graves, Hashimoto's, 
atrophic, silent and postpartum thyroiditis) are examples of 
common diseases in which immunogenetic factors play a role 
in their pathogenesis. Familial studies have shown that in 
monozygous twins 50-60% and in dizygous twins nearly 10% of 
siblings develop the condition (Schieusener et al, 1989). 
These results underline the significance of genetic factors, 
but also indicate that non-genetic factors, for instance 
environmental parameters could play a role in triggering the 
autoimmune process.
It appears that multiple genes are involved, but as yet 
have not been identified. These include the major 
histocompatibility complex (MHC) restricted and non MHC 
restricted genes (Farid, 1987).
The MHC genes termed HLA (human leucocyte antigen) in man 
are highly polymorphic and are located on the short arm of 
chromosome 6. This 3800 kilobase region spans from the class 
II region (HLA DP, DQ, DR) over the class III (complement, 
21-hydroxylase) to the class I region (HLA B, C, A)(Hansen & 
Nelson, 1990; Badenhoop etal, 1990).
The HLA molecules play a key role in antigen recognition 
and immune response. Class I molecules are found on all 
nucleated cells and platelets, and appear to be involved 
primarily in the presentation of antigen to cytotoxic T 
lymphocytes (CTL); Whereas class II molecules are limited in 
distribution and are involved in antigen presentation to 
helper T (Th) and T suppressor/inducer (TSi) lymphocytes 
(Hansen & Nelson, 1990). They are normally present on the
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surface of vascular endothelial cells, B lymphocytes, 
Langerhans cells, macrophages, some epithelial cells and 
activated T cells, but can be "induced" on endocrine tissue 
such as thyrocytes (Farid, 1987). Both class I and II 
molecules are capable of binding specific peptides derived 
from processed antigen.
Many studies using DNA- hybridisation analyses, termed 
restriction fragment length polymorphism (RFLP) have probed 
the HLA region genes and have shown an association of 
certain genes with susceptibility to autoimmune thyroiditis.
Hashimoto's thyroiditis has been reported to be associated 
with the HLA specificities DR4, DR5 and DQw7 (Badenhoop et 
al, 1990). Atrophic thyroiditis (primary was found
to be associated with HLA B8 and DR3 with a compensatory 
decrease in DR5 (reviewed by Farid, 1987). Postpartum and 
silent thyroiditis have been associated with HLA DR4 in 
several studies (Farid, 1987; Maenpaa et al, 1989) .
In Graves disease the HLA system has been studied in much 
greater detail. The data suggested that one of the important 
genes is in linkage disequilibrium with HLA-B8 and HLA-DR3 
(Schieusener et al, 1989).
Linkage disequilibrium arises within populations when 
particular allelles at closely linked loci occur together on 
the same chromosome more often than would be expected by 
chance (Knight & Adams, 1982).
The C4AQ0 allele (complement) which is in linkage 
disequilibrium with HLA-B8 and DR3 has also been reported to 
be associated with Graves disease and other autoimmune 
disorders such as insulin dependent diabetes melitus (IDDM)
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(Ratanachaiyavong et al, 1989).
Relapse in Graves disease has been observed to have a 
strong correlation with DQA2U allele which is highly 
associated with HLA-DR3 (Ratanachaiyavong et al,1989).
The other group of genes extensively studied and shown to 
have a moderately strong association with Graves disease are 
those coding for immunoglobulin heavy chains (Gm). Gm(1, 2, 
21) and Gm f, b or Gmf, n, b have been reported to have an 
increased frequency (reviewed by Tamai et al, 198 6; Farid, 
1987) when compared to the normal population. The data 
suggests that recessive genes in linkage disequilibrium with 
these IgGl and IgG3 markers are important in the 
susceptibility to Graves disease. Both the Gm and HLA genes 
are believed to interact and enhance the susceptibility to 
the disorder (Farid, 1987).
Another interesting trait is that these autoimmune thyroid 
disorders are more prevalent in women. This tendency may be 
related to the effect of sex steroids on immunoregulatory 
mechanisms; Although the possibility that X chromosome genes 
are implicated, cannot be ruled out (Farid, 1987).
In conclusion, the immunogenetic basis of these diseases 
is very multifactorial and is still poorly understood. The 
interaction between these loci for susceptibility is 
complex, it is therefore not surprising that difficulties 
arise in predicting susceptible phenotypes.
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1.1.3 Environmental Factors Affecting- Autoimmune Thyroid
Pls.g£S.e.s.J.
The- possibility that environmental factors may play a role 
in the pathogenesis and progression of autoimmune thyroid 
disease (AITD) in genetically predisposed people has been a 
popular theory for several years, although difficult to 
prove (Safran et al, 1986).
Infectious agents such as viruses and bacteria have long 
been suspected as etiologic agents in many autoimmune 
diseases, including insulin dependent diabetes melitus 
(IDDM) , systemic lupus erythremdrb?s[s (SLE) and rheumatoid 
arthritis (RA). For example, IDDM has been strongly linked 
with Mumps and Coxsackievirus B4 infections (Yoon, 1990; 
Helmke et al, 1986; Foulis, 1990).
In AITD various groups have reported a linkage between the 
prevalence of Graves disease with that of antibodies to 
Yersinia enterolitica (Volpe', 1988; Heyma et al, 1986). 
This has led to suggestions that antibodies against a 
bacterial protein might cross react with the TSH receptor on 
the thyrocyte and thus cause autoimmune disease (Byfield et 
al, 1989; Heyma et al, 1986). Other reports have shown 
thyrotropin binding proteins cross reacting with AITD 
autoantibodies from a number of organisms, including 
Escherichia coli strains (Byfield et al, 1989) .
Retroviruses have also been implicated in AITD, since they 
can effect many parameters of immune function and have been 
associated with autoimmunity in several animal models (Krieg 
& Steinberg, 1990). Ciampolillio et al, (1989) detected 
retroviral like sequences in Graves disease patients.
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suggesting the possibility of a novel exogenous retrovirus. 
This could be acquired in early life, remaining silent for 
years until unknown factors precipitate the disease. Other 
studies have failed to confirm this report (Humphrey et al, 
1991). Another virus that has been linked in AITD has been 
influenza B virus (Safran et al, 1987).
Increasing evidence has suggested that environmental 
factors such as drugs, stress and dietary iodine play an 
important role in the expression of AITD. Epidemiologic 
studies have suggested that AITD is more common in areas of 
iodine sufficiency than areas of iodine deficiency (Safran 
et al, 1987; Boyages et al, 1989). Drugs such as amiodorone 
and lithium are known goitrogens. Between 7~ 62% of 
psychiatric patients on lithium therapy have reported 
goitres. It has been shown to inhibit thyroid hormone 
release, disrupt the iodine concentrating mechanism and 
inhibit the synthesis of iodotyrosines (reviewed by Safran 
et al, 1987).
Clearly further detailed work is necessary to help further 
define the environmental effects on the progression of AITD. 
If these factors can be shown as "trigger" agents of the 
disease, then the implications f o f prevention are enormous.
1.1.4 Possible Mechanisms. Q£_ Autoimmune Disease
The exact pathogenic mechanisms leading to thyroid 
autoimmunity are still not clear; Most current theories 
either implicate dysregulation within the immune system 
(Cohn & Atlan, 1989; Volpe', 1988) or speculate on idiotype 
anti-idiotype cross reactions (Cooke et al, 1984). There are
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objections to both models however, it is still possible to 
suggest a plausible sequence of events (Wilkin, 1989) .
Long before the clinical onset of thyroid autoimmune 
disease (AITD), there is evidence of humoral and cell 
mediated activity against cell autoantigens (Bottazzo,
1989). These observations led to the theory that 
environmental factors, such as bacteria and viruses could 
render the thyrocyte vulnerable to immune attack.
It has been proposed that these "agents" could modify 
antigens, resulting in altered self, or possibly possess 
antigenic epitopes that cross react with thyroid specific 
antigens. For example, this molecular mimickry has been 
reported between Yersinia enterocolitica and the thyrotropin 
receptor (Heyma et al, 1986). Such an agent could sensitise 
T-helper cells which in turn could activate B lymphocytes 
into secreting autoantibody.
Recently it has been demonstrated that viral infections 
such as Reovirus type 3 (Neufeld et al, 1989) can induce 
inappropiate MHC class II expression on thyrocytes in 
primary culture. It is generally believed that the viral 
insult causes a rise in cytokines such as gamma interferon, 
which then exerts a diverse range of effects on the cellular 
and molecylof function of the thyrocyte, including the 
induction of MHC class I & II (King et al, 1989; Kraiem et 
al,1990).
This discovery has led to the hypothesis that aberrant 
expression of HLA-DR antigen on thyrocytes would enable them 
to present thyroid specific antigen directly to helper T 
cells, thus initiating and maintaining the AITD process
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(Bottazzo, 1983). This model has been further supported by 
the recent demonstration of retroviral-like sequences 
present in the DNA extracted from thyroid glands of patients 
with Graves disease (Ciampolillo et al, 1989). The same 
retroviral sequences have not been detected in non 
autoimmune pathologies and unrelated human tissues, strongly 
supports the concept of a new exogenous retrovirus. However, 
this hypothesis is unlikely to be the full story since the 
AITD would progress rapidly and autoimmune phenomena 
following viral infections would not be limited to a non 
pathological process. In fact in AITD there is a prolonged 
latency period and the autoimmune phenomena following viral 
infection are transient (Iwatani et al, 1989).
Other studies have proposed that aberrations in the 
idiotype network (recognition by one antibody for the 
combining site of another) may be the cause of organ 
specific autoimmunity (3inha et al, 1990). There is evidence 
that the immune system in normal individuals contains low 
circulating levels of auto reactive B and T lymphocytes 
which have the latent ability to produce autoantibody 
(Bankhurst et al, 1973).
Deregulation or defects in the T suppressor cells have 
also been implicated (Volpe' et al, 1988) in the autoimmune 
mechanism. It can be envisaged that these immunocytes could 
lose control of the humeral response (eg autoantibody 
production) thus leading to failure of self tolerance 
(Bottazzo, 1989; Sinha et al, 1990). The T cell fault theory 
would also help to explain the antigenic specificity of 
AITD. Another characteristic of AITD that lends support to
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the imbalanced idiotype network model is the tendency for 
spontaneous exacerbations and remission (Paschke et al,
1990), This supports a fluctuating balance between positive 
and negative regulatory factors (such as T helper versusT 
suppressor lymphocytes) in the disease progression (Kraiem 
et al, 1992; Weetman, 1992).
In summary AITD (1) develops in genetically susceptible 
individuals, (2) may be triggered by environmental agents 
operating by non specific inflammation or molecular 
mimickry, or both, (3) is the result of the sum of genetic 
and environmental factors that overide normal mechanisms of 
self tolerance, and (4) is often mediated by T cells or is 
characterised by an underlying defect or deregulation in the 
T cell compartment (Sinha et al, 1990).
In conclusion, a better knowledge of self tolerance at the 
molecular level is necessary before a full understanding of 
the autoimmune mechanism is achieved.
1.2.1 Thyroid Autoantiaens.
There are at present three distinct and well characterised 
thyroid autoantigens. These are; thyroglobulin, thyroid 
peroxidase (the microsomal antigen/ TPO) and the 
thyrotropin receptor, these are discussed in detail below.
1.2.2 T h M f op l obu 1 in.
Thyroglobulin is a large watersoluble glycoprotein that 
functions as a prohormone in the synthesis of thyroxine and 
triiodothyronine. The protein consists of two identical 
subunits, each with a molecular weight of 330,000. It is
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synthesised in the thyrocytes and is secreted into the 
thyroid lumen, where it is stored (Edelhock, 1985).
It was first demonstrated to be an autoantigen by a 
precipitin reaction technique using thyroid homogenates and 
plasma from patients with Hashimoto's disease (Roitt et al, 
1956). However, it was not until recently, that recombinant 
DNA technology permitted the structure and epitope mapping 
of the molecule to be determined.
The human Tg monomer consists of 2748 amino acids with 
repetitive sequences at the N- terminal end, which are 
important for it's tertiary structure (Maltiery et al, 
1987). Despite it's large size, there are only four thyroid 
hormono^e-biC sites, all situated on the extremities of 
the molecule (Furmaniak et al, 1990).
Tg only has a limited number (2-3) autoantibody binding 
sites, whereas heterologous antibodies can be directed 
towards as many as fourty different determinants on the 
molecule (Chan et al, 1987).
Autoantibodies to Tg have been reported to cross react 
with acetylcholinesterase and optical fibres (Weetman et al, 
1987); However, sequence homologies suggest that the genes 
encoding these proteins have evolved from a common ancestral 
gene (Furmaniak et al, 1990).
The measurement of anti- Tg autoantibodies is useful in 
the diagnosis and follow up of autoimmune thyroid disease. 
There is a tendency for the autoantibody titer to. be higher 
in Hashimoto's thyroiditis than in Graves disease.
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1.2.3 Thyroid Peroxidase (Microsomal antigen/. TPQ)^
Over 30 years ago the existence of a second thyroid 
autoantigen distinct from thyroglobulin was discovered using 
a complement fixation technique (Belyavin et al, 1959) . 
However, it wasn't until recently that this antigen was 
determined to be thyroid peroxidase, the enzyme involved in 
the iodination of tyrosines \n thyroglobulin (Tg) (Furmaniak 
et al, 1990).
This enzyme contains a haem group essential for activity, 
and is capable of utilising H202 for catalysing the 
formation of monoiodotyrosine (MIT), diiodtyrosine (DIT), 
thyroxine (T4) and triiodotyrosine (T3) /nto the Tg
molecule. It is a membrane bound enzyme that is principally 
located in the intracellular compartment and on the apical 
surface of the thyroid cells (Nilsson et al, 1987).
Autoantibodies to the microsommal antigen have been shown 
to be associated with both subclinical and active autoimmune 
(Hashimoto's) thyroiditis (Weetman et al, 1984; Banga & 
McGregor, 1991). They are believed to be of greater 
importance than those directed against Tg in the 
pathogenesis of Hashimoto's disease. Since they are closely 
associated with the active phase of the disease, they are 
commonly used as a clinical diagnostic marker (Ruf et al,
1987).
In 1987 cDNA library studies allowed the successful 
cloning and expression of the autoantigen in an "active" 
form that was immunologically recognised by human 
autoantibodies (Kaufman et al, 1989). Furthermore, the gene 
involved is now known to be located on the short arm of
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human chromosome 2 and codes for a lOlKDa protein consisting 
of 933 amino acids arranged in a single loop linked by a 
disulphide bridge (Kimura et al, 1987).
The availability of purified autoantigen will permit the 
analysis of autoantibody/ antigen interaction at the 
molecular level and perhaps reveal it's significance in the 
overall autoimmune process.
1.2.4 The Thyrotropin (TSH) Receptor.
The thyrotropin receptor (TSHR) is an integral membrane 
glycoprotein which is present on the surface of thyroid 
epithelial cells (Rees Smith et al, 1987) and fat cell 
membranes (lida et al, 1987; Roselli-Retifuss et al, 1992). 
The binding of TSH to the receptor results in a hormone- 
receptor complex which interacts with the regulatory units 
of adenylate cyclase, via a G protein (Gs) within the cell 
membrane. This interaction results in the production of 
cyclic AMP which mediates most, if not all the actions of 
the hormone (Furmaniak et al, 1987).
The first strong evidence that the receptor was an 
autoantigen came in 1956 by Adams & Purves with the 
discovery of thyroid stimulatory activity quite distinct 
from TSH. This was later shown to be due to autoantibodies 
(termed LATS, long acting thyroid stimulator. Reviewed by 
Dorrington & Munro, 1966).
Initial study and characterisation of the receptor was 
difficult due to it's relatively low expression (103-104 
sites per cell) (Furmaniak, 1990) and it's ease of
degradation during purification procedures (Akamizu et al.
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1988). Early studies tended to use Triton X100 solubilised 
thyroid membranes in conjunction with a range of standard 
biochemical techniques, including lectin affinity 
purification (Kress & Spiro, 19 8 6) , ion exchange
chromatography (Islam & Farid, 1985), immunoprécipitation 
(Heyma et al, 1984), TSH affinity chromatography (Leedman et 
al, 1989), cross linking studies (Kajita et al, 1985) and 
monoclonal antibodies (Cosagliola et al, 1991). These and 
numer.ous other reports have produced a vast array of TSH 
binding membrane components of varying mass, eg 300K, 200K, 
175K, 130K, 90K, 55K, 30K (Chan et al, 1987).
Thus the structure of the receptor was rather confusing 
with conflicting data and with various proposed models (Chan 
et al, 1987; Furmaniak, 1987).
However recently using polymerase chain reaction (PCR), 
Libert et al, (1989) took advantage of the sequence homology 
displayed by all the known G- protein coupled receptors to 
amplify and clone the TSHR.
Using oligonucleotides corresponding to conserved 
transmembrane regions of the G-protein, a cDNA thyroid dog 
library was probed. At moderate stringency a cDNA encoding a 
4.9Kilobase thyroid specific transcript was identified. It 
encoded for a polypeptide containing 398 amino acid 
residues, consisting of a putative extracellular domain 
connected to a 346 residue carboxyl terminal domain that 
contains seve n transmembrane segments (Parmentier et al,
1989). This structure has a 45% sequence homology with the 
luteinising hormone (LH) receptor and nearly 70% when 
transmembrane regions are compared (Furmaniak et al, 1990).
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Figure 1.3 & Schematic Representation ££ ISHzTSg 
Receptor interaction. ^ Modified From Furmaniak & Rees.
gmithf.. 1990)..
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Using the dog receptor clone, a human gtll cDNA library 
was screened allowing for the human TSHR to be identified 
(Libert et al, 1989). The cloned antigen has been expressed 
in xenopus oocytes, Y1 cells and COS cells then shown to 
specifically bind to TSHR autoantibodies.
Insitu hybridisation experiments on human metaphase 
chromosomes using cDNA probes has allowed the location of 
the receptor to be determined (Rousseau-Merck et al, 1990) . 
It was located to chromosome 14q31 whereas the LH receptor 
is located on 2p21.
The cloned receptor would give a peptide chain length 
around 90,OOOKda and 120,OOOKda (judged by SDS gels) when 
glycosylated. This would be in general agreement with the 
model proposed by Furmaniak, (1987), of the receptor with 
two subunits 55Kda and 35Kda based on photoaffinity 
labelling studies (Kajita et al, 1985) . Figure 1.3 shows a 
schematic representation of the TSH receptor complex.
The availability of purified autoantigen that can be 
expressed and recognised by autoantibodies will hopefully 
lead to a greater understanding of TSHR TSHR-autoantibody 
interaction at the molecular level, and it's significance in 
the disease status.
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1.2.5 Other Autoantiaens.
Additionally, other autoantigens have been reported in the 
literature but their clinical and diagnostic significance is 
not yet understood. They are;
64Kda Antigen.,
This autoantigen was isolated and purified from a gtll 
human thyroid cDNA library, screened using Hasimoto's sera. 
The cDNA clone encodes for an autoantigen common to the 
thyroid and eye muscle tissues; It may therefore have a 
relevance in the pathogenesis of Graves opthalmopathy (Dong 
et al, 1991).
Autoimmune Thyroid Related Antigen (ATRAI.L^
ATRAI autoantigen is a 107Kda protein isolated from a gtll 
human thyroid cDNA library screened using a potent human 
anti microsomal antisera. It is believed to be a fragment/ 
subunit of a more complex protein held together by 
disulphide bonds, but it's actual identity or clinical 
significance are not yet known (Hirayu et al, 1987).
7OKU Antigen.
The KU autoantigen is a nuclear, DNA binding heterodimer 
of 70Kda and 86Kda proteins. While it's function is unknown, 
the KU antigen is a target of autoantibodies to several 
autoimmune conditions including (SLE) systemic lupus 
erythematosus, Hashimoto's thyroiditis and Graves disease 
(Allaway et al, 1990).
The recombinant protein was originally isolated and
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purified from a gtll thyroid library using immunoglobulins 
from a Graves disease patient (Chan et al, 1989).
Recently using immunoflouresence techniques this "strict" 
nuclear protein has been shown to be expressed on the 
surface of the plasma membrane of normal cells. This 
expression may help to explain how nuclear antigens, 
apparently inaccessible to the immune system can become 
targets of an autoimmune attack (Prabhaker et al, 1990).
The Second Colloid Antigen (CAJ
Structurally very little is known about this autoantigen. 
It is usually detected using immunofluoresence techniques, 
giving a "ground glass" pattern on staining (Skrakosch et 
al, 1982; Williams & Goodburn, 1983).
Aproximately 10% of the normal population and nearly 50% 
of thyroid patients (Hashimoto's & Graves disease) have 
autoantibodies directed against CA2. This autoantigen 
appears to have little clinical significance and is 
therefore not usually carried out in routine investigation 
(Doniach et al, 1979; Williams & Goodburn, 1983; Trotsenburg 
et al, 1989).
Fraoraeus Cell Surface Antigen-*.
This autoantigen has been detected on viable suspensions 
of human thyroid cells by immunofluoresence studies. 
Autoantibodies to this antigen produce a "patchy" staining 
on the cell surface distinct from TPO, TSHR and Tg 
(Fragraeus et al, 1970; Williams & Goodburn, 1983).
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1.3-1 Thyroid Cell Lines As Models F_o_r_ The, gfcuidg Q£.
Autoimmune Disease.
Early studies on understanding the mechanism of thyroid 
cell growth, differentiation and function were dependent 
upon cells being isolated directly from whole tissue and 
maintained in primary culture. Due to the difficulties in 
obtaining human tissue, porcine, bovine and canine cell 
preparations were commonly used as thyroid cell models (Eggo 
et al, 1985).
Whilst in many respects these primary cells show several 
characteristics of the original tissue, they are fraught 
with problems; 1) Primary thyroid cells are inherently 
unstable even in short time culture (1-2 weeks) . 
Dedifferentiation and progressive loss of response to 
thyrotropin occurs. 2) Isolated thyroid cultures although 
principally composed of follicular cells, will also contain 
a "contaminant" population of fibroblasts. These when in 
continuous culture proliferate rapidly relative to the 
thyrocytes. This has frequently caused difficulty in 
determining alterations in biochemistry and function to a 
specific response. 3) Finally tissue variation particularly 
that derived from human pathological origin, makes accurate 
conclusions about response difficult (Bidey et al, 1988).
To overcome these problems, various laboratories have 
attempted, with some success to immortalise the thyrocyte 
and produce a stable cell line.
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1.3.2 Existing Thyrocyte Line.s.^
A brief review of thyroid derived cell lines sited in the 
literature is presented below;
Fisher Rat Thyroid Cell Line (FRThJ-,.
This was the first reported stable cell line derived from 
thyroid follicles. The FRTL strain was isolated from primary 
culture using semi defined medium (termed 6H) containing six 
hormones or growth factors; insulin, thyrotropin, 
transferrin, hydrocortisone, somatostatin and glycl-L- 
histidyl-L-lysine acetate (Ambesi-Impiom, ato et al, 1980;
1986) .
Subsequent cloning of this cell line gave rise to FRTL-5 
which has been widely used as a model for autoimmune studies 
and general thyroid cell biochemistry (Davies et al, 1987) .
The line has been stable in continuous culture for more 
than five years and has been observed to maintain highly 
differentiated features such as thyroglobulin (Tg) secretion 
and iodide uptake. However, the line does not incorporate 
iodide into the Tg molecule, does not synthesise thyroid 
hormones, T3, T4 and lacks the ability to reorganise into 
three- dimensional "pseudofollicular" form in culture 
(review; Bidey et al, 198S’) •
Wistar Rat Thyroid Cell Line (WRT).
The WRT strain was generated from primary rat thyroids in 
a similar manner to FRTL using 6H media (Brandi et al,1987). 
The line has the ability to synthesise thyroglobulin, 
concentrate iodide and contains a TSH dependent adenylate
28
cyclase system. The WRT cells have been stable in continuous 
culture for more than three years without loss of thyroid 
differentiation (Rotella et al, 1989).
Ovine Thyroid Cell L i m  .(QVDil.S- 5B),.«-
A stable cell line was derived from primary sheep 
thyrocytes using 6H media (Fayet & Hovsepian, 1985). After 3 
years continuous culture the line still showed TSH 
modulation of cAMP and thyroglobulin secretion (Hovsepian et 
al, 1986; Fayet et al, 1986).
Porthos 5H Cell Line.
This porcine thyrocyte line was prepared from primary 
culture using 6H defined media and was stable for 1 year in 
culture. The line produced Tg, T3, T4, and has a TSH
dependent adenylate cyclase system (Fayet & Hovsepian,
1985).
Human Cell Line (SGHTL-34).
Normal human thyrocytes were immortalised by 
electroporation mediated transfection with the plasmid 
pSV3neo (contains SV40 early regions). One resultant cell 
line was observed to secrete Tg and demonstrated a 
morphological change in response to TSH (Whitley et al,
1987); However the cells contain 10 copies of SV40 in their 
genome and show senescence in long term culture (Taylor et 
al, 1990).
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SV40 Immortalised Thyrocyte Lines^
The virus SV4 0 has been used in a number of reports to 
immortalise human thyroid cells, (Belfiore et al, 1991; Eggo 
et al, 1990; Wynford-Thomas et al, 1990; Davies et al, 1989; 
Martin et al, 1990). All these lines initially expressed 
thyroid characteristics, but in long term culture become 
senescent due to SV40 "crisis” (Taylor et al, 1990).
Human Monoclonal Cell
A human monoclonal thyroid cell line was obtained by 
fusing normal thyrocytes with a human lymphoblastoid cell 
line (GM1500 6TG-A12; Croce et al, 1980) by standard 
hybridoma technology (Karsenty et al, 1985).
The selected line showed many characteristics of "normal" 
thyrocytes in primary culture, including Tg secretion, 
iodide uptake, T3 and T4 production, expression of TSH 
receptor (Reemy et al, 1987) and microsomal antigens; 
However the line showed it's hybrid nature by secreting 
immunoglobulin IgG. It also cannot incorporate iodine into 
the Tg molecule, it lacks a cAMP signal pathway (Karsenty et 
al, 1988) and cannot form follicles in culture. Contrary to 
the original paper, the GEJ line has been reported to be 
unstable in long term culture (Lemoine et al, 1989).
TPC-1 Cell Line..
TPC-1 is a human papillary thyroid carcinoma cell line 
which secretes Tg and is used for oncogene research. It is 
reportedly stable in long term culture (Tanaka et al, 1987; 
Ishizaka et al, 1990).
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Thyrocyte/ X Cell Hybridoma (PY2-.1.5.)...,.
The line was generated by fusing thyroid cells from a 
Graves patient with a hypoxanthine- aminopterin- thymidine 
(HAT) sensitive variant of the human T cell leukemia line 
(Molt 4-8AG) . The estabilished line showed TSH 
responsiveness and was stable in long term culture. However, 
no other thyroid specific functions could be detected or 
induced (Martin et al, 1988).
Human (12S) Cell Line.
A retroviral vector constructed containing adenovirus E1A 
oncogene and the neomycin phosphotransferase gene was used 
to infect human foetal thyrocytes. One line was selected and 
shown to possess TSH mediated cAMP generation as well as the 
differential expression of HLA class II antigens in response 
to recombinant Gamma interferon. 12S was reported to be 
stable for over 18 months in continuous culture (Cone et al,
1988).
1.4 Project Aims.
The primary aim of this study was to immortalise human 
thyrocytes using heterohybridoma technology. This technique 
would hopefully enable the production of stable cell lines 
which would express the common thyroid autoantigens, such as 
thyroglobulin, thyroid peroxidase and the TSH receptor.
Existing human thyrocyte lines have generally been SV4 0 
transfected. These have tended to be of limited value due to 
their inherent instability and their gradual loss of thyroid 
phenotypic characteristics in long term culture.
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Karsenty et al, (1985), produced a monoclonal thyrocyte 
cell line, termed GEJ using the human lymphoblastoid fusion 
line GM1500-6Tg. This thyroid cell line showed various 
thyrocyte characteristics, but suffered from chromosome 
instability in continuous culture.
To further this research approach, second (mouse X human X 
human) and third (mouse X human X human X human) generation 
human heterohybridomas would be utilised for a human 
thyrocyte fusion. Previous human heterohybridomas have only 
been used on lymphocytes but have allowed successful stable 
cell lines to be established (De Silva et al, 1991; Moyle et 
al, 1989).
The initial stages of the research would concentrate on 
the development and validation of assays (eg thyroglobulin 
determination) necessary for the initial screening the 
fusion lines.
The secondary aims would be to investigate the phenotypic 
nature of the novel hybrid lines produced and to determine 
their suitability as a human thyrocyte model.
The final targets of this project were to develop and 
validate an ELISA for TSH receptor autoantibodies which 
would be rapid, simple to run and ideal for the large scale 
screening of patient sera. It was also hoped that a human 
thyrocyte cell line which expressed TSH receptors could be 
used as the ELISA antigen coating material. Initial ELISA 
development would use primary porcine thyrocytes .
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CHAPTER ZHÛ
DEVELOPMENT OF AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
FOR THE DETECTION OF HUMAN THYROGLOBULIN.
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2.1.0 General Introduction.
This chapter describes the production of murine 
monoclonals to human thyroglobulin and their subsequent use 
in the development of a specific ELISA. The assay was 
primarily developed for screening thyroglobulin secretion 
into tissue culture medium (see chapter 3), but it's 
suitability for a human serum assay was also evaluated.
2.1.1 Thyroglobulin, It's Measurement And Role In Disease.
Thyroglobulin (Tg) is a large glycoprotein with a
molecular weight of 660,OOOthat acts as a precursor in the 
synthesis of Tg and T4. It is synthesised by the thyroid 
follicular cells, and is secreted by vesicle exocytosis into 
the colloid space, where it is stored. En route the Tg 
molecule is iodinated by thyroid peroxidase on the interface 
of the apical microvilus membrane and the colloid lumen 
(Retetoff & Lever, 1983).
The vast proportion of the Tg produced is reabsorbed by 
the follicular cells, where upon it is hydrolysed to release 
the thyroid hormones into general circulation. However, a 
small proportion escapes as intact Tg and enters the blood 
via the lymphatic system. The synthesis and secretion is 
normally under the control of TSH, although in certain 
pathological states other factors such as autoantibodies and 
drug therapy can alter Tg levels.
In the normal population serum Tg levels range from the 
undetectable up to 60ng/ml with a mean around 10ng/ml 
(0.0 3nM); Moderately higher concentrations are found in 
maternal and newborns (10-200ng/ml). Elevated levels can
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also be observed in active Graves disease and other 
conditions causing thyroid hyperfunction. Very high levels, 
sometimes greater than 5ug/ml, can also occur in 
differentiated thyroid cancers (follicular, papillary and 
Hurthle cell carcinoma) (Schlossberg et al, 197 9; Reiners,
1986) .
Serum Tg has been commonly used as a diagnostic tumour 
marker for thyroid carcinoma. It has also been used to 
assess the level of thyroidal stimulation in pathological 
states, such as Graves disease (Bodlaender et al, 1978; 
Bayer & McDougall, 1984; Wilson et al, 1989; Aizawa et al,
1990). However, perhaps the most useful application of serum 
Tg measurement is in the monitoring of post-operative 
carcinoma patients for indications of relapse.
The majority of assays for Tg determination reported in 
the literature are either double antibody radioimmunoassay 
(RIA), or immunoradiometric (IRMA) assays (for examples see; 
Bodleander et al, 1978; Spencer et al, 1985; Shlossberg et 
al, 1979; Bayer & Kriss, 1979). These methods have tended to 
be rather slow (typically 48 hours) and are generally 
unreliable due to the presence of serum anti-Tg 
autoantibodies competing for antigenic epitopes (reviewed 
Feldt- Rasmussen & Krogh- Rasmussen, 1985).
More recently ELISA detection systems have been developed 
(Kilduff et al, 1985; Endo et al, 1979) which in general are 
more robust , rapid and cost effective than conventional RIA 
for large scale screening. However, these procedures also 
suffer from autoantibody interferences which can either 
falsely elevate or lower observed Tg concentrations. In
35
patients with autoimmune thyroid disease or rheumatoid 
arthritis Tg autoantibodies are particularly prevalent. 
Reportedly upto 56% of Graves serum samples are ^ antibody 
positive. To overcome this problem, several groups have 
raised murine monoclonals to specific epitopes on the human 
Tg molecule that are not autoantigenic (Pfahl et al, 1988). 
Alternatively many commercial assays by companies such as 
RSR Ltd, Cardiff and Henning, Berlin recommend that a serum 
Tg recovery test be determined on each sample to allow for 
assay "correction" (Bayer & Kriss, 1979).
2.1.2 Production (2f Murine Monoclonals._
The production of antigen specific monoclonal antibodies 
by hybridoma technology is now routinely carried out in many 
areas of biological research. The technique usually involves 
the fusion of antigen stimulated B lymphocytes with a 
continuous growing myeloma cell line, termed the fusion 
partner.
This line imparts "immortality" to the lymphocyte allowing 
it to proliferate and secrete antibody in long term culture. 
The procedure was originally carried out using Sendai virus 
as a "fusogen" (Kohler & Milstein, 1975, 1976), but was 
later replaced by polyethylene glycol (PEG) (Pontecorvo, 
1976) due to the difficulty in removing the virus from the 
cell culture medium.
More recently, hybridomas have been generated by 
electrofusion which is reportedly more efficient than 
conventional hybridisation methods (Schmitt et al, 1989). 
Cells are orientated by a non uniform electric field and
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then fused by applying a pulse of high frequency energy 
(Samoilovich et al, 1987).
The most popular fusion partners utilised today lack the 
enzyme, hypoxanthine guanine phosphoribosyl transferase 
(HGPRT), which is responsible for the incorporation of 
hypoxanthine into DNA. The lack of this DNA salvage pathway 
enzyme allows researchers, after fusion, the ability to 
select (lymphocyte X myeloma) hybridomas from the 
heterogeneous mixture of fused and unfused cells.
This selection is achieved using HAT medium (Littlefield, 
1964) which contains aminopterin, hypoxanthine and 
thymidine. Aminopterin is a folic acid analogue that binds 
to folic acid reductase, thus blocking the co-enzymes 
required for de novo synthesis of D NA. Under these 
conditions only hybrid cells which contain the DNA salvage 
pathway and conferred immortality will proliferate. All 
primary cells, myeloma cells and other hybrids such as 
lymphocyte X lymphocyte and myeloma X myeloma will 
eventually die in culture.
General monoclonal antibody production is thoroughly 
reviewed by Coding (1986).
More recently the possibility of producing murine 
monoclonals in bacteria has been investigated. Briefly, 
murine or human DNA libraries are prepared in bacteriophage 
lambda. Each plaque in the library can express antibody 
heavy and/or light chain proteins. When co-expressed, the 
chains can assemble to form FAB fragments or antibodies 
(Ward et al, 1989; Sastry et al, 1989) .
37
EXPERIMENTAL METHODS
All cell culture reagents were obtained from Gibco, 
Paisley, Scotland, unless otherwise stated in the text.
All chemicals were obtained from Sigma Chemicals, Dorset, 
England.
9 9.1Tmmnnization And Production &f Antibodies^.
Polyclonal antibodies were raised against human Tg 
(Calzyme Laboratories INC, San Luis, California, USA ) in 
sheep and BALB/C mice by the methods described by Coligan et 
al, 1991.
Briefly, sheep 1827, 1645 & 1646 (Guildhay Antisera Ltd) 
were initially immunized with lOOug of Tg in Freunds 
modified non-ulcerative adjuvent (B Morris, University Of 
Surrey). Later intramuscular boosts of 50ug were given. 7-10 
days after each immunisation, bleeds were normally taken and 
their antibody titer assessed by ELISA according to the 
methods described in 2.2.7.
After several immunizations, the mouse with the highest 
antibody titer was selected for fusion.
2.2.2 Preparation £f Spleen. Cells.,.
3 days after the final boost the chosen BALB/C mouse was 
killed by cervical dislocation followed by complete 
immersion in 70% ethanol. Using sterile forceps and scissors 
the skin and peritoneum were cut, then drawn back to reveal 
the spleen. This was removed and transferred to a 50ml 
sterile pot (Sterilin Ltd, Hounslow, UK). The washed spleen
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was cut open in a sterile 20ml petri dish (Sterilin) and the 
clumps of cells teased apart in 15ml RPMI-164 0 medium 
(Gibco, Scotland).
The cells were washed 3 times by centrifugation (800g, 3 
minutes) and finally resuspended in 10 ml of RPMI-1640. The 
number of viable cells (excluding obvious red blood cells) 
were determined by Trypan blue exclusion (Tenant, 1964).
2.2.3 Cell Fusion Partner.
The fusion partner chosen was SP2/0-Agl4 (hereafter 
abbreviated to SP2) which is a non synthesising, non 
secreting variant of the hybrid cell line P3/X63-Ag8 
(obtained from the EACC, PHLS, Porton Down, UK).
The cell line is 8-azoguanine resistant and is therefore 
susceptible to HAT (hypoxanthine, aminopterin, thymidine) 
selection (Littlefield, 1964).
The SP2 line was maintained in RPMI-1640 medium 
supplemented with 10% V/V foetal calf serum, 2mM pyruvate 
and 2mM glutamine. They were incubated at 37°C in an 
atmosphere of 10% C02 in air and were subcloned every 2-3 
days to keep the cell density between 1-6 X 105 cells/ml.
Prior to the fusion, cells were washed 3 times and finally 
resuspended in 10ml RPMI-1640. The total number of viable 
cells were determined by Trypan blue exclusion (Tenant, 
1964).
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2.2.4 Fusion Procedure.
1) The spleen cells and the fusion partner (SP2) were 
mixed in the ratio 5:1 (3.3 x 106 spleen cells : 0.7 x 106 
SP2 cells), and were pelleted in a sterile 50ml centrifuge 
tube (ICN FLOW, Irvine, Scotland) by centrifugation at 800g 
for 3 minutes. The supernatant was decanted and the tube 
inverted for 2 minutes to ensure a dry cell pellet.
2) The cells were fused using 50% polyethylene glycol 
(PEG) 1300-1600 (Sigma Chemicals, St Louis, USA) prepared in 
RPMI-1640 medium (Lane et al, 1984).
3) Using a sterile pipette (ICN FLOW), 1ml of this PEG 
solution was added drop wise to the cell pellet over a 1 
minute period, whilst gently swirling the centrifuge tube. 
Following a 1 minute incubation with gentle mixing 1ml RPMI- 
1640 was added dropwise to the cell suspension. A further 
10ml of RPMI-1640 were added in the next 8 minutes to further 
dilute out the PEG.
The volume was slowly increased in the next 5 minutes up 
to 40ml. The cells were then pelleted by centrifugation at 
800g for 3 minutes.
4) The cells were gently resuspended in 8 0ml of cold HAT 
medium containing 20% V/V foetal calf serum, 2mM glutamine, 
2mM pyruvate and 10% V/V BM-Condimed HI (Boeringer Mannheim 
GmbH) and plated out into 4 96 well tissue culture plates 
(NUNC, Roskilde, Denmark). The plates were incubated at 37°C 
in an incubator gassed with 5% C02 in air.
BM-Condimed is a growth factor concentrate obtained from 
activated human leukocytes (Stein & St Clair, 1988), which 
can reportedly extend cell lifespan. Here it replaces the
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need for murine spleen feeders.
5) Wells were topped up with fresh HAT media 6 days post 
fusion. This was repeated every 3 days or when cell medium 
became acidic.
2.2.5 Initial Screening And Expansion Q f  Hybridomas.
8 to 10 days post fusion, when small hybridoma colonies 
were visible microscopically, supernatants were removed and 
assayed in the thyroglobulin monoclonal screening assay 
(2.2.7). Later supernatants were also run in the mouse 
immunoglobulin quantitation assay (2.2.6).
Positive colonies upon reaching confluency in 9 6 wells 
were transferred to 24 well plates and refed with RPMI-1640 
containing 10% V/V foetal calf serum and HT (hypoxyxanthine, 
thymidine). Positive lines upon being transferred were 
cloned by limiting dilution at 3 levels (10, 1 and 0.1
cells/well).
Clones that were again positive in the screening assay 
were expanded into flasks (NUNC) and all the supernatants 
collected.
"High" immunoglobulin secreting hybridomas were cloned out 
once more, expanded then cryopreserved by the methods 
described in section 3.2.4.
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2.2.6 Enzyme Linked Immunosorbent Assay (EL.I.$A_L Ear Muring.
IgG .
A simple ELISA was used to determine the secretion of 
murine immunoglobulin in tissue culture supernatants.
All reagents were obtained from Sigma Chemicals unless 
otherwise stated in the text. The following buffers were 
required;
Assay Buffer (PBSGT) pH7.4. 
containing
NaCI
KC1
KH^PO,
Na2HP04 (anhydrous) 
Gelatin 
Tween 20 
Thiomersal
136mM 
2. 6mM 
1.5mM 
20mM
0.1% W/V 
0.05% V/V 
0.02% W/V
Substrate Buffer (Citrate phoshate). pH5.t_5.
Na2HP04
Citric acid
h2o2
The pH was adjusted with concentrated NaOH.
50mM
25mM
0.04% V/V
200ul of 10ug/ml DEAE purified donkey anti-mouse antisera 
(Guildhay Antisera Ltd, Guildford, UK) were coated onto 
maxisorb microtitre plates (NUNC, Denmark) by absorbtion at 
pH9.6 in 0.1M bicarbonate buffer at 37°C. The plates were 
washed twice with PBSGT, followed by a 30 minute "blocking" 
step (400ul of 1% V/V B.S.A per well).
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200ul of sample and standards (Sigma l-10 0 0ng/ml Gamma 
globulins) were applied to the plate in duplicate and 
incubated for 30 minutes at 37°C. The plate was washed twice 
with PBSGT, followed by the addition of Horse radish 
peroxidase conjugated donkey anti-mouse.
After 30 minutes incubation at 37°C the plate was again 
washed with PBSGT and then tapped dry. The colour was 
produced by the addition of substrate reagent; 3,3',5,5'- 
tetramethyIbenzidine (hereafter abbreviated to TMB) 
(Boehringer Mannheim, West Germany) in citrate phosphate 
buffer pH5.5 containing 0.04% hydrogen peroxide (Bos et al, 
1990%.
After 30 minutes at 37°C, the colour reaction was stopped 
by the addition of 50ul of 2.5M sulphuric acid and the 
absorbance was read at 450nm on a Titertek Multiscan Plus 
(Flow Laboratories, High Wycombe, UK). Sample concentrations 
were determined from the constructed standard curve.
2 . 2 . 7  Thyroglobulin Monoclonal Screening Assay.,.
An ELISA detection system was employed to determine the 
specificity of the murine monoclonals produced. The assay 
involved human thyroglobulin precoated ELISA plates being 
incubated with tissue culture supernatants. Any bound murine 
antibodies were then detected by subsequent incubation with 
an anti-mouse enzyme labelled conjugate.
Assay Protocol^
Polystyrene maxisorb microtitre wells (NUNC, Denmark) were 
coated with human thyroglobulin (Calzyme Laboratories INC, 
USA) at lOug/ml in 0.1M bicarbonate buffer pH9.6, overnight
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at 4°C. Wells were washed 3 times with assay buffer (PBSGT) 
and stored at 4°C until required. 200ul aliquots of tissue 
culture supernatants were applied and incubated for 30 
minutes at 37°C. Following a further wash step, the colour 
was produced by the addition of TMB substrate in citrate 
phosphate buffer (Bos et al, 1982). The reaction was 
terminated by the addition of 50ul of 2.5M sulphuric acid 
and the absorbance read at 450nm On a Titertek Multiscan 
Plus (ICN FLOW, UK).
Sample values that were more than 2 standard deviations 
greater than the negative control were regarded as positive 
for thyroglobulin antibodies.
For the screening of sheep polyclonals (2.2.1) the above 
conjugate was replaced with a Donkey anti sheep HRPO.
2.2.8 Murine Antibody Subclassing Dot Blot.
2ul of mouse subclass chain specific antisera (The Binding 
Site Ltd, Birmingham, UK) were dotted onto cellulose nitrate 
paper (Anderman, Schleicher & Schuell, Germany) and allowed 
to air dry. The paper was blocked for 30 minutes with 20% 
V/V foetal calf serum in RPMI-1640 then washed 3 times with 
PBSGT buffer. Tissue culture supernatants were applied to 
the paper and incubated for 30 minutes at room temperature.
After washing the paper, donkey anti-mouse HRPO conjugate 
was applied. Following a further wash step, bound 
immunoglobulin was visualised by the addition of chromagen 3 
amino-9-ethylcarbazole (ABC) (Sigma) in 0.1M acetate buffer 
pH5.5 containing 0.04% H202 (Graham et al, 1965).
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ASSAY PEVELOPMEEL-
2.2.9 Preparation Of A Thyroglobulin Affinity, Column.
Sheep anti-thyroglobulin polyclonals were affinity
purified before use in assay development.
Ig of amino activated porous glass beads (1000A, 10Ou 
diameter, Clifmar Associates, Guildford, UK) were weighed 
out into a glass bottle. 5ml of 5% V/V glutaraldehyde 
(Sigma) in 0.1M bicarbonate pHS.O containing 0.9% V/V saline 
were added and roller mixed for 2 hours room temperature. 
The beads were washed batch wise, allowing them to settle 
four times with bicarbonate buffer pH8.0.
4 0mg of thyroglobulin (Calzyme Laboratories, INC, USA) 
dissolved in 10ml bicarbonate buffer were applied to the 
beads and the protein allowed to bind for 2 hours at room 
temperature. Unbound ligand was eluted off the beads with 
bicarbonate buffer. The remaining active sites were "capped" 
with 10ml of 0.2M glycine in bicarbonate buffer pHS.O for 2 
hours. Following a further wash step the beads were packed 
into a 1 X 10 cm disposable column (Biorad Laboratories, 
Watford, UK) and stored at 4°C until required.
2.2.10 Affinity Purification Q f  Antisera.
The thyroglobulin affinity column was thoroughly 
equilibrated with bicarbonate buffer pH8.0. 5ml of sheep 
polyclonal antisera or concentrated monoclonal supernatant 
were applied to the beads 4 times. The column was then 
washed with buffer to remove any unbound protein. Bound 
antibodies were desorbed and eluted with 25mM glycine-HCl 
pH2.2. 4ml fractions were collected and the absorbance at
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280nm determined. The protein peak was pooled and thoroughly 
dialysed against 5L PBS pH7.4 for 48 hours. The column was 
re-equilibrated with bicarbonate buffer.
2.2.11 Preparation Of IgM On Protamine Sulphate $epherose_,_
Protamine sulphate coupled to sepharose has been 
previously used to adsorb IgM from mouse and human serum 
(Hudson & Hay, 1989). The binding is thought to be due to an 
interaction between the negatively charged areas of the IgM 
molecule and positive groups on the protamine. The bound 
protein is normally eluted using high salt concentrations. 
This basic procedure was used to affinity purify the 
monoclonals from tissue culture supernatants.
Preparation Of Immunadsorbent.
o
10g of cyanogen bromide (CNBr) activated sepharose 4B 
(Pharmacia LKB, Uppsala, Sweden) were suspended in ImM HC1 
(lOOml/g) for 15 minutes. The slurry was poured into a glass 
column and washed with 100ml of coupling buffer (0.1M sodium 
bicarbonate pH8.3, containing 0.5M sodium chloride.)
Ig of protamine sulphate, grade X from salmon, (Sigma) 
dissolved in 75ml of coupling buffer were added to the gel 
and roller mixed for 2 hours at room temperature. Excess 
ligand was washed away using the coupling buffer. Any 
remaining active sites were "capped" with Tris-HCl buffer 
(0.1M, pH8.0) containing sodium chloride (0.5M). The column 
was stored at 4°C in the presence of 0.1% W/V sodium azide.
46
Purification Of IgM From Tissue Culture gjupejcnat ant S.,.
Tissue culture supernatants were pooled and concentrated 
using an Amicon Ultra filtration System (Amicon Ltd, 
Stonehouse, UK). This concentrate was then applied to the 
protamine sulphate gel (previously equilibrated with 0.08M 
phosphate saline buffer pH7.4 containing 0.077M Nad) and 
stirred for 4 hours at 4°C.
The gel was repacked into a chromatography column and 
washed with further phosphate saline buffer. Bound protein 
was eluted with 0.08M phosphate buffer containing 1.1M NaCl. 
The eluate was concentrated and dialysed against Tris-HCl 
buffer 0.1M pH7.4. The preparation was further purified by 
gel filtration on a sepharose S300 column (Pharmacia, LKB, 
Uppsala, Sweden) to remove possible ceruloplasmin and IgA 
contamination.
2.2.12 Conjugation Of Antibody T& Alkaline Phosphatase.
The procedure used is based on that of Mahan et al, 1987, 
differing principally in the time scale of reactions. 
Briefly the alkaline phosphatase is reacted with the hetero­
bifunctional reagent succinimidyl 4-(N-maleimidomethyl) 
cyclohexane-l-carboxylate (SMCC) through a primary amine 
group. This results in a maleimide labelled enzyme. 
Sulphydryl groups are then incorporated into the antibody by 
the use of 2-Iminothiolane (2IT). The addition of the 
antibody to the activated enzyme results in a highly 
stable linkage.
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The following buffers were used;
0 .2M TSMZ (Triethanolamine/saline) pH7 t 3. 
Triethanolamine 14.9g/L
NaCl 5.80g/L
1M Magnesium chloride/0.1M Zinc chloride 1ml/ml
stock solution.
Q.2M TSE (Triethanolamine/saline/EDTA) pH9 t,5 
Triethanolamine 14.9g/L
Nacl 5.8g/L
EDTA (di-sodium salt) 0.37g/L
Q.2M TSE (Triethanolamine/saline/EDTA) pH7.t.3.
Triethanolamine 14.9g/L
NaCl 5.8g/L
ED TA 0.37g/L
A typical (1:1 molar ratio) 2mg conjugation is described 
below;
1)Activation Of Alkaline Phosphatase With SMÇÇ^
2 0 Oui of a 10mg/ml alkaline phosphatase solution 
(Enzymatix, Cambridge, UK) were pipetted into a glass vial. 
lOul of 2OmM SMCC (Pierce & Warriner Ltd, Chester, UK) 
dissolved in dimethyl formamide (BDH) were added and reacted 
for 15 minutes at room temperature. The reaction was stopped 
by the addition of 2ul 1M glycine pH7.3 (l/100th reaction 
volume) and gently mixed for 5 minutes. The activated enzyme 
was then desalted into TSMZ pH7.3 using a pre-equilibrated 
PD10 column (Pharmacia, Uppsala, Sweden). The absorbance at
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280nm of the fractions were determined, the "protein peak" 
pooled and stored at 4°C.
9.) Activation Of Antibody With 2IT.
2mg of antibody were desalted into TSE pH8.5 using a pre­
equilibrated PD10. The "pooled protein peak" obtained 
(typically 2.5ml) was placed into a glass vial. 25ul 
(l/100th volume) of lOOmM 2IT (Pierce & Warriner Ltd, 
Chester, UK) dissolved in TSE pH8.5 containing lOOmM NaOH 
were then added and allowed to react for 30 minutes at room 
temperature. The reaction was stopped by the addition of 
25ul of 1M glycine pH7.3 then gently mixed for 5 minutes. 
The activated antibody was then desalted into TSE pH7.3 
using a pre-equilibrated PD10. The protein peak was pooled 
and stored at 4°C.
3) Conjugation.
The activated alkaline phosphatase and antibody solutions 
were mixed together. 2ul of 1M magnesium (II) chloride were 
added for each ml of antibody solution present. The reaction 
was then gently mixed at room temperature for 2 hours 
followed by 18 hours at 4°C.
The reaction was terminated by the addition of lOul of 
lOmM N-ethylmaleimide (Pierce & Warriner Ltd, Chester, UK) 
dissolved in TSE pH7.3, per ml of conjugate present. The 
conjugate was stored at 4°C until purification by gel 
filtration.
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2.2.13 Conjugation Of Antibody Tq. Horse Radish Peroxid&SJSU.
The purified antibodies were coupled to horse radish 
peroxidase (HRPO) using a refinement of the two step 
periodate method (Beyzavi et al, 1987) . The periodate is 
used to oxidase 1,2-diol linkages within the carbohydrate 
moiety of the enzyme, to form reactive aldehyde groups. 
These groups are then reacted with amino groups on the 
antibody to form a stable Schiff-base linkage (Kricka,
5mg of HRPO (Enzymatix, Cambridge, UK) dissolved in 1ml 
distilled water, were mixed with 20Oui of 0.1M sodium 
periodate. After 30 minutes gentle mixing, the solution was 
dialysed against ImM sodium acetate buffer pH4.4 overnight 
at 4°C. 5mg of purified antibody were desalted into 0.1M 
bicarbonate buffer pH9.6 using a pre-equilibrated PD10. The 
absorbance at 280nm of the pooled fractions were determined 
and the protein peak pooled. The dialysed enzyme was added 
to the antibody and mixed for 2 hours room temperature.
The reaction was terminated by the addition of 0.5ml 
ethanolamine buffer pH8.0 (5% V/V ethanolamine containing
0.05M glycine. After 30 minutes gentle mixing the resultant 
conjugate was dialysed against 5L PBS containing 0.02% W/V 
thiomersal, then stored at 4°C until required.
2.2.14 Tg ELISA Optimisation Studies.
Initial ELISA optimisation was undertaken using 2 affinity 
purified sheep polyclonal bleeds (1645, 1646). However, the 
resultant assay gave very poor sensitivity.*
To overcome this problem a series of studies were
1985) .
( d e t e c t io n  LIMIT .'_WAS„ DETERMINED
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performed using the newly prepared monoclonals in 
conjunction with the affinity purified ovine polyclonals. 
Enzyme labelled polyclonals and monoclonals were tried in 
various assay arrangements The monoclonal 4C4A5 emerged as 
the most suitable in an ELISA assay format and was thus 
studied further. Variations in coating concentrations, 
incubation times, conjugate dilution and choice of enzyme 
label were all examined before the final assay format was 
achieved.
2.2.15 Final Assay Protocol.
The following buffers and reagents were required;
Assay Buffer (TBT) pH7.4.
Tris-HCl 5 OmM
B.S.A (fraction V) 0.1%W/V
Tween 20 0.05%W/V
Sodium azide 0.2%W/V
Substrate Reagent (PMPI pH8 , $_■>.
Diethanolamine 1M
Sodium chloride 150mM
Magnesium chloride (1M stock) Iml/L
Phenolphtalein monophosphate 9g/L
The buffer is initially made and the pH adjusted to 8.6 
with concentrated HC1. The phenolphtalein monophosphate 
(Enzymatix Ltd, Cambridge, UK) is then added.
51
Polystyrene maxisorb microtitre plates (NUNC, Denmark) 
were coated with affinity purified sheep 1827 anti human 
thyroglobulin antibodies at 5ug/ml in 0.1M bicarbonate pH9.6 
overnight at 4°C. The plates were then decanted, allowed to 
air dry and stored at 4°C until required.
20Oui of thyroglobulin standard (range 0-1000ng/ml 
prepared in tissue culture media or pooled normal human 
serum) and samples were incubated in the wells for 2 hours 
at 37°C. All yvnect.sur e - w e r e  carried out in
duplicate.
After washing with TBT buffer, monoclonal 4C4A5 labelled 
alkaline phosphatase conjugate was applied to all the wells 
and incubated for 2 hours at 37°C.
Following a final wash stage, PMP substrate reagent was 
added and the colour allowed to develop for 30 minutes. The 
reaction was terminated by the addition of 50ul of 3M NaOH. 
The absorbance was read at 550nm on a Titretek Multiscan 
Plus (FLOW). Sample concentrations were determined from a 
constructed standard curve.
2.2.16 Evaluation Of The Proposed Thyroglobulin ELI SA t.
The specificity, precision and detection limits of the 
assay were determined by standard procedures,(Caraway, 
1971).
The suitability of the proposed ELISA for the 
determination of thyroglobulin in patient sera was also 
investigated. Briefly, 75 Graves patient sera, 2 Lyphochecks 
(Biorad Laboratories, Kernel Hempstead, Hertfordshire, UK)
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and 4 thyroid carcinoma samples (Patsey Prescott, St Lukes 
Hospital, Guildford, UK) were assayed according to the 
standard methodology
RESULTS
2.3.1 The Cell Fusion.
Hybridisation of the immunized spleen cells with the SP2 
myeloma cell line was successful in producing over 300 
hybridoma colonies. 86 of these were initially positive in 
the Tg ELISA screening assay 2.2.7 and were transferred to 
2ml wells.
10 of these colonies were subsequently cloned by limiting 
dilution. Positive clones from the plates were recloned, 
cryopreserved by the methods described in 3.2.4, and finally 
expanded to allow preliminary characterisation studies to be 
undertaken.
2.3.2 Pnrification And Characterisation Qf_ The Monoclonal
Antibodies .„
The immunoglobulin subclasses of the monoclonals obtained 
were determined by a simple dot blot assay system. The 
results obtained are presented in Table 2.1.
The murine monoclonals were successfully purified from 
culture supernatants by the use of affinity chromatography 
(Protamine sulphate for IgM and Tg affinity for IgG). 
Typical antibody yields were between 1-4^^/ml, as determined 
by murine immunoglobulin ELISA (Figure 2.2).
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2.3.3 Optimisation Qf_ The Thyroglobulin ELI SA.
Preliminary experiments involving optimisation of antibody 
plate coating whilst varying the monoclonal conjugate, 
revealed that ovine polyclonal 1827 in combination with 
monoclonal 4C4A5 were the best assay pairing.
The alkaline phosphatase labelled monoclonal was deemed 
superior to the horse radish peroxidase conjugate on the 
grounds of assay reproducibility and lower non specific 
binding (NSB). Further studies involving subtle variation in 
the antibody titer, sample size, and assay incubation times 
allowed the final protocol to be accomplished. A typical 
standard curve is represented in Figure 2.3.
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Table 2.1 The Immunoglobulin Subcla.S-S.ea Q£ The. MC>nOClC>na.l 
AntibPdies^ .
ANTIBODY B A M  la CLASS. LISHI CHAIN
2A11F6 IgM Kappa
32A5A IgM Kappa
32B9B IgM Kappa
2C4B1 IgM Kappa
4C4A5 IgG Kappa
1E52C IgG Lambda
2C4A2 IgG Kappa
7G14D IgG Kappa
7D2B2 IgG Kappa
3A21F IgG Kappa
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2.3.4 Evaluation Of The Proposed Thyroglobulin EL.I.SA,. 
Specificity.
The specificity of the ELISA was assessed by measuring the 
apparent thyroglobulin response caused by high levels of 
various potentially cross reactive analytes.
No significant cross reactivity was observed. The data are 
presented in Table 2.4 
Reproducibility.
To determine intra assay precision, three spiked tissue 
culture medium pools were assayed 16 times. The day to day 
precision was assessed by analysing aliquots of 2 pools for 
10 working days. The data are shown in Tables 2.5 and 2.6. 
Theoretical Detection Limit.
20 replicate samples of human thyroglobulin free media 
were assessed by the standard assay procedure. The results 
obtained were utilised in the following equation and 
determined to be 10ng/ml.
Minimum detection limit = 3 X SD of the replicate blank.
Patient Serum Analysis.
Analysis of the Graves sera and commercial lyphochecks 
confirmed that the ELISA did not have the required 
sensitivity for patient serum analysis. However, The four 
thyroid carcinoma patient sera revealed very high 
thyroglobulin levels (900ng/ml, 1300ng/ml, 600ng/ml and
1100ng/ml respectively).
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Table 2.4 Cross Reactivity S.tüdy Within The Thyroglobulin
ELISA..
COMPOUND %CROSS-REACTIVITY
100
96
<0.001
<0.001
<0.001
Human Tg 
Bovine Tg 
L-Thyroxine 
Triiodothyronine 
Triiodoacetic acid
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Table 2.5 Intra assay Precision Q£ Human Thyroglobulin
ELIS^ u
HUMAN Ig (ng/ml y SU £50il TERMS lûl
798.3 22.887 2.86 16
196.25 8.062 4.10 16
30.33 1.662 5.48 16
Where CV = Coefficient of variation.
SD = Standard deviation.
Table 2.6 Between Day Precision Q£ The Human Thyroglobulin
ELIS^ u
HUMAN la (ny/miy SS CV(%). TERMS ini
810 33.33 3.86 10
192 9.391 4.87 10
Where CV = Coeficient of variation. 
SD = Standard deviation.
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2.4 Discussion.
This chapter describes the development of murine 
monoclonal antibodies against human thyroglobulin and their 
subsequent utilisation in a simple ELISA system.
The mouse-SP2 fusion successfully produced many specific, 
stable antibody secreting hybridomas which were cloned and 
characterised.
After antibody purification from concentrated tissue 
culture supernatants, preliminary studies were undertaken to 
determine a compatible ovine polyclonal - murine monoclonal 
pairing suitable for sensitive thyroglobulin detection. The 
major obstacle at this stage was competition for a common 
target epitope on the molecule by the antibody pair.
Eventually these initial experiments revealed that the 
monoclonal 4C4A5 in combination with affinity purified 
polyclonal 1827 gave the optimum system. Following final 
optimisation, the proposed assay format was evaluated for 
it's suitability in screening patient serum and tissue 
culture supernatants for the presence of thyroglobulin.
The assay was found to perform well, being specific, 
relatively rapid and reproducible. However, the sensitivity 
was limited (10ng/ml), making it unsuitable for the 
screening of human patient serum.
The possibility of using an amplification step to increase 
the sensitivity was also examined. For example, using the 
monoclonal 4C4A5 labelled with fluoresc&Th isothiocysmde 
(FITC), followed by sheep anti-FITC alkaline phosphatase 
conjugate as an amplification stage. These systems were 
eventually rejected due to the high background interference
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from bovine thyroglobulin present in the foetal calf serum.
In retrospect, improvement in the assay sensitivity could 
have been achieved with higher affinity monoclonals which 
would not cross react with bovine thyroglobulin. This might 
have been achieved with a longer mouse immunization schedule 
and early screening for bovine thyroglobulin cross 
reactivity. Initial antibody screening for only IgG would 
have been advantageous, since this would have avoided the 
stability problems associated with the use of IgM molecules.
In summary, this study describes a specific ELISA suitable 
for the rapid screening of thyroglobulin tissue culture 
supernatants, but not of human serum.
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CHAPTER THREE
HUMAN THYROCYTE HETEROHYBRIDOMA FUSION AND INITIAL
SCREENING.
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3.1 GENERAL INTRODUCTION.
The aim of this study was to establish a stable human cell 
line with the morphological and physiological features of a 
normal human thyrocyte using heterohybridoma techniques. The 
model line would enable the investigation of various thyroid 
pathologies such as Graves or Hashimoto's disease at the 
molecular level.
Previous cell models, such as the rat FRTL5 (Ambesi- 
Impiomabato et al, 1980) and WRT (Brandi et al, 1987) cell 
lines have yielded a great deal of information about general 
thyroid biochemistry. However, these lines suffer from one 
major disadvantage in that they are of animal origin. 
Species antigenic differences make these lines of limited 
value in autoimmune studies, although they are still 
commonly used in research for autoantibody bioassay (Kohn et 
al, 1986) .
Several human thyrocyte lines have been reported in the 
literature (Karsenty et al, 1985; Whitley et al, 1987), but 
they have all been unstable in continuous culture (Taylor et 
al, 1990; Lemoine et al, 1989).
Below is a review of previous human cell immortalisation 
technologies ;
3.1.2 Immortalisation Of Human Cells.
Many cell lines can be established from primary cells by 
passage in vitro. By this procedure it is relatively easy to 
establish fibroblastic lines from several species including 
mouse, rat and rabbit, whereas human cells are refractory to 
establishment (Linder & Marshall, 1990).
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Human cells when passaged in vitro, reach a fixed number 
of cell doublings, a stage of no proliferation, in which the 
cells become quiescent and cell division ceases. This is 
sometimes referred to as cellular senescence (Shay et al, 
1991). To overcome this problem, various laboratories have 
utilised hybridisation technology, or have employed DNA 
tumour viruses as possible ways to override the cellular 
programme of agetr (Linder & Marshall, 1990) .
3.1.3 Transformation Using DNA Tumour Viruses.
Several DNA tumour viruses encode for proteins which can 
efficiently override the human cellular programme of ags’< ^  
The viral genes involved are often observed cooperating with 
other oncogenes such as ras or middle-T, to produce the 
transformed state (Chang, 1986).
The viral encoded proteins are commonly localised in the 
nucleus and are believed to exert transcriptional regulatory 
activities within the malignant cell. It has been postulated 
that either these immortalising oncogenes provide functions 
that are inactive within the senescent cell, or that the 
genes overcome the effects of growth suppressor activity in 
the senescent cell (Linder & Marshall, 1990).
Human Papillomavirus type 18 (HPV-18) has been
successfully used to immortalise kératinocytes (Hurlin et 
al, 1991).
An adenovirus E1A construct has been used to transform 
human thyrocytes. However, the line showed very few 
phenotypic characteristics of the primary cell. (Cone et al,
1988).
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By far the most commonly used tumour viruses are the 
Epstein-Barr virus which is specific for B lymphocytes, and 
the Simian virus 40 (SV40) which has a more diverse range or 
transforming abilities. These two are critically examined in 
more detail below;
Epstein-Barr Virus Transformed B cells.
The Epstein-Barr virus (EBV) is a lymphotropic herpesvirus 
that causes infectious mononucleosis (glandular fever). EBV 
can be used to selectively transform human B lymphocytes 
that have the CR2 complement receptor on the plasma membrane 
(Carson & Freimark, 1986; Casali & Notkins, 1989), allowing 
the cells to proliferate indefinitely in medium lacking 
exogenous growth factors.
This transformation technique has been widely used in the 
production of specific human monoclonals to a variety of 
antigens, eg viruses and streptococci (Casali et al, 1986; 
Steinitz et al, 1977; Corny et al, 1989; Garzelli et al,
1986). However, several problems have limited the 
application of this method. These are as follows;
1) In order to maintain specific antibody production early 
cloning of the infected lymphocytes is essential. This is 
due to the polyclonal nature of the antibody secretion after 
transformation.
2) The transformed B lymphocytes often grow inefficiently at 
low cell density, causing major problems when cloning.
3) The cell lines are relatively unstable in continuous 
culture, typically losing antibody secretion within six
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months.
Despite these problems, EBV transformation has been widely 
used in many laboratories to produce permanent human cell 
lines (Carson & Freimark, 1986) .
Immortalisation With Simian Virus 4_Q. (SV40) .
The most widely used viral agent for transforming human 
cells is SV40. It is a DNA tumour virus of the papova family 
which can transform a wide variety of human cells, including 
pancreatic islets (Soldevila et al, 1991), thyroid 
epithelial cells (Wynford-Thomas et al, 1990; Lemoine et al, 
1989), fetal kidney fibroblasts, kératinocytes, bronchial 
epithelial cells, amniocytes and monocytes (for a review of 
these and other lines refer to Sack, 1981 and Chang, 1986).
The transformation of mammalian cells by SV40 requires the 
expression of the early region within the viral genome, 
which encodes for two proteins termed large T-antigen 
(94Kda) and the small t-antigen (17Kda).
The large T-antigen is believed to be necessary for the 
initiation of transformation and maintenance of the 
transformed phenotype, whilst the small t-antigen may have a 
qualitative effect on this event (Chang, 1986).
The infection of human cells with SV40 is semi-permissive, 
so that while it can lead to the transformed phenotype, it 
can also lead to lytic infection and the release of progeny 
virus.
Typically after a period of weeks (6-10) in continuous 
culture, the transformed cells reach a stage of little or no 
proliferation, where the cells continue to cycle, but die at
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such a high rate that most of them are lost. This phenomenon 
is commonly termed crisis (Chang, 1986; Taylor et al, 1990). 
Very few cells ever escape crisis to become true immortal 
cell lines.
Therefore, in summary, SV40 transfected cells are a useful 
tool in studying human cell biology, but their limited life 
span and their tendency to lose phenotypic characteristics 
in culture makes them of limited value in terms of thyroid 
models.
3.1.4 Hybridisation £>f Human Cells.
Human cell hybridisation (Cell fusion) at present is still 
limited to the immortalisation of B lymphocytes. The 
technologies involved, although based on the murine 
hybridoma system are still hindered by the lack of 
satisfactory human fusion partners (Watts et al, 19 9 0; 
Mcknight et al, 1990).
Early hybridisation studies used murine myeloma lines such 
as NS-1 to produce (mouse X human ) hybrids that secrete 
human antibody. These interspecies hybridomas were found to 
preferentially segregate human chromosomes, making it 
extremely difficult to derive stable cell lines producing 
antibody. Chromosomes 14 and 22 are usually retained whilst 
chromosome 2 is lost (Kozbor et al, 1986; Croce et al, 
1980) .
More recently to overcome these problems, many groups have 
used these non secreting (human X mouse) hybrids as the next 
generation fusion partners (Carroll et al, 1986; Sugiyama et 
al, 19 91; Teng et al, 1983). These heterohybridoma fusion
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partners have produced many stable cell lines secreting 
human antibody (De Silva et al, 1991; Samoilovich et 
al,1987) .
The possibility of using human hybridoma technology on 
other cell types appears to have only been briefly 
investigated. The Fusion of a human thyrocyte with a T cell 
hybridoma has been reported to have produced a stable line, 
but lacking most of the thyroid phenotypic characteristics 
(Martin et al, 1988).
More successfully Karsenty et al, 1985 used a human 
lymphoblastold cell line (GM1500 6TG-A12) to produce a 
hybrid thyroid cell line with many characteristics of the 
normal thyrocyte. The hybrid nature of the cells were 
confirmed by the detection of antibody and thyroglobulin in 
the tissue culture supernatants. This line however, has been 
reported to be unstable in long term culture (Lemoine et al,
1989).
The possibility of using heterohybridoma fusion partners 
in cell fusion other than B lymphocytes has not been 
investigated.
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EXPERIMENTAL METHODS
All cell culture reagents were obtained from Gibco, 
Paisley, Scotland, unless otherwise stated in the text. 
Chemicals were obtained from Sigma Chemicals, Dorset, UK.
3.2.2 Preparation Q£_ Human Thyrocytes
The patient selected for the fusion experiment was a 25 
year old caucasion female with benign adenoma of the 
thyroid, which could no longer be controlled by standard 
drug therapy. Prior to theatre she was treated with 
propylthiouracil to inhibit iodine uptake by the gland.
After thyroidectomy (Mr Miggins; Southampton General 
Hospital) two small tissue samples (1cm3) were cut from the 
lobes and transferred directly into sterile RPMI-1640 medium 
(Gibco Ltd, Scotland) supplemented with penicillin (100 
units/ml) and streptomycin (100 units/ml). The tissue was 
stored on ice until arrival at the laboratory. Each specimen 
was treated separately, thus allowing two fusions to be 
carried out.
Thyrocytes were prepared by collagenase digestion 
(Rappoport et al, 1982) with a few minor modifications. The 
tissue was cut into l-3mm chunks using sterile forceps and a 
scalpel. 10ml of collagenase/dispase (Boehringer Mannheim, 
West Germany) solution (4mg/ml) prepared in RPMI-1640 were 
added and incubated for 30 minutes at 37°C in an atmosphere 
of 10% C02 in air (C02 incubator, LEEC Ltd, Nottingham, UK) . 
The resultant suspension was washed three times by 
centrifugation in RPMI-1640 (8 00 X 3 minutes, 25°C), then
resuspended in 10ml. The total number of viable cells
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present were determined microscopically by Trypan blue 
exclusion (Tenant, 1964).
3.2.3 The Cell Fusion Partners.
The cell fusion partners chosen to immortalise the human 
thyrocytes were second (mouse x human x human) and third 
generation (mouse x human x human x human) heterohybridomas, 
hereafter abbreviated to HFP2A and HFP3 (Kindly donated by 
Dr N Ebsworth, University Of Surrey). The development of 
these fusion partners is schematically shown in Figure 3.1.
These lines were selected for their lack of immunoglobulin 
secretion and their "good" growth characteristics in 
culture. They were made 8- azoguanine resistant by the 
methods of Ostberg et al, 1983 and were therefore 
susceptible to HAT (hypoxanthine, aminopterin, thymidine) 
selection.
Briefly the heterohybridomas were maintained and 
subsequently cloned in media containing 2Oug/ml of 8- 
azoguanine (Sigma). Resistant cell lines were regularly 
checked for HAT sensitivity before fusion.
The lines were maintained in RPMI-1640 medium supplemented 
with 10% V /V foetal calf serum, 2mM glutamine, 2mM pyruvate 
(Gibco, Paisley, Scotland) and were grown typically at a 
density between 2-4xid>cells/ml.
Prior to fusion, cells were washed 3 times by 
centrifugation (BOOg, 3 minutes) and finally resuspended in 
10ml RPMI-1640 medium. The total number of viable cells 
present were determined.
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Figure 3.1. Conventional mouse X human hvbridomas were 
constructed by fusing NS-1 cells human peripheral
lymphocytes (PBL). Hybrids were selected with HAT medium. & 
non secreting line was treated with 8-azoguanine (8AZA), 
then refused with PBLs to produce s. second generation fusion 
partner. Repetition of these stages produced the third 
generation fusion partner (Modified from Ostberg Pursch, 
1 9 8 3 ) .
MURINE H I  
FUSION PARTNER
HAT SELECTION
FIRST GENERATION 
FUSION PARTNER 0
NON SECRETING 
HYBRIDOMA
HAT SELECTION
{  8 AZA
HAT SELECTION
HFP2A
0
SECOND GENERATION 
FUSION PARTNER
|  BAZA
HFP3 0 THIRD GENERATION FUSION PARTNER
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3.2.4 Cryopreservation And Recovery Qf. Cells.
Cell lines were cryopreserved by the following "in house" 
procedure. Typically cells that were in log phase growth 
were spun down (800g, 3 minutes) and gently resuspended in 
cold freezing medium (a mixture containing 10% V/V dimethyl 
sulphoxide (DMSO) in foetal calf serum) to a density between 
1-7 X 106 cells/ml. The suspension was then aliquoted into 
2ml cryotubes (NUNC, Denmark), placed in a polystyrene box 
and frozen overnight to -70°C. For long term storage, 
cryotubes were transferred to a liquid nitrogen container 
(1/Air Liquid, France) .
Recovery of frozen cells was achieved by quickly thawing 
the cryotube in a 37°C waterbath. The cell suspension was 
then carefully mixed into 30ml of culture medium and 
centrifuged at BOOg for 3 minutes, to remove the toxic DMSO. 
The cell pellet was finally resuspended in fresh medium and 
cultured in an atmosphere of 10% C02 at 37°C.
3.2.5 Cell Hybridisation, 
fusion One;
1) The human thyrocytes and the fusion partner HFP3 were 
mixed in the ratio 1: 1 (4.12 X 106 thyrocytes; 4 X 106 HFP3 
cells). They were then were pelleted in a sterile 50ml 
centrifuge tube (ICN FLOW, Irvine, Scotland) by 
centrifugation at BOOg for four minutes. The supernatant was 
decanted and the tube inverted for two minutes to ensure a 
"dry" cell pellet.
2) The cells were fused using 50% W/V polyethylene glycol 
(PEG) 1300-1600 (Sigma Chemicals, St Louis, USA) prepared in
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RPMI-1640 medium.
3) Using a sterile pipette (ICN FLOW), 1ml of this PEG 
solution was added dropwise to the cell pellet over a 1 
minute period, whilst gently swirling the centrifuge tube.
Following a 1 minute incubation with gentle mixing, 1ml 
RPMI-1640 was added drop wise to the cell suspension. A 
further 10ml of RPMI-1640 was added in the next 8 minutes to 
further dilute out the PEG. The volume was slowly increased 
in the next 5 minutes up to 40ml. The cells were then 
pelleted by centrifugation at BOOg for 3 minutes.
£_) The cells were gently resuspended in 120ml of cold HAT 
medium containing 20% V/V foetal calf serum, 2mM glutamine, 
2mM sodium pyruvate, penicillin 100units/ml, streptomycin 
100units/ml (Gibco, Paisley, Scotland) and plated out into 
five 96 well tissue culture plates (NUNC, Roskilde, 
Denmark). Microscopically the cells at this stage had a 
"lumpy" appearance. The plates were incubated at 37°C in a 
C02 incubator.
S') Wells were topped up with fresh HAT media 8 days post 
fusion. This was repeated every 3 days when the cell medium 
had become acidic.
Fusion Two.
5 X 106 human thyrocytes were fused with 4.9 X 106 HFP2A 
cells according to the methods described in fusion one 
above.
The fused cell pellet was resuspended in 150ml of cold HAT 
media containing 10% V/V foetal calf serum, 2mM glutamine, 
2mM sodium pyruvate, penicillin 100units/ml, streptomycin
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lOOunits/ml, 1% V/V Nutridoma-NS (Boehringer Mannheim, GmbH, 
West Germany), and plated out into five 96 well tissue 
culture plates.
Twenty days post fusion, cell culture media were removed 
from the wells containing visible cell colonies. These 
supernatants were saved for analysis.
3.2.6 Expansion And Screening Qf_ Hybrid Call Lines.».
Hybridoma colonies which had grown to confluency in the 96 
well tissue culture plates were transferred to 24 wells (2ml 
per well) and refed with 20% V/V foetal calf serum 
containing HT (hypoxanthine, thymidine). Supernatants were 
regularly collected and screened in the following range of 
assays;
Thyroglobulin ELISA 
t3 RIA
Human immunoglobulin ELISA.
Any colonies detected showing secretion were cloned out by 
limiting dilution at 3 levels (10, 1, 0.1 cells/well) in 96 
well tissue culture plates. Clones were again screened for 
secretion and any positive clones were expanded. When lines 
were large enough they were transferred to 25ml flasks and 
refed with 10% V/V foetal calf serum supplemented with 
pyruvate and glutamine.
Cell lines upon reaching confluency in small flasks (25ml) 
were cryopreserved by the methods described in section 
3.2.4. A cell bank (5 vials) of each colony was prepared to 
allow further characterisation at a later date.
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3.2.7 Determination Of Thyroglobulin In Tissue CultU.re
Supernatants
Tissue culture supernatants from the thyroid derived cell 
lines were screened using the proposed ELISA described in 
section 2.2.15. Initially HFP3, HFP2a and SP2 supernatants 
were used as negative control media.
3.2.8 Radioimmunoassay Q f  3,3',5-Triiodo-Lthyronine.
Tissue culture supernatants from the thyroid derived cell
lines were screened for the presence of T3 by a simple 
radioimmunoassay.
In this assay, binding sites on the thyroid binding 
globulin (TBG) within the foetal calf serum were blocked by 
the addition of 8-anilo-l-naphthalene sulphonic acid (ANS) 
(Aldrich, Gillingham, UK) to prevent assay interference. As
a result of this, the method measures total T3.
The T3 present in the sample and a tracer amount 125-I-T3
compete for binding sites of the ovine T3 monoclonal.
Separation was achieved by precipitation using PEG reagent.
The following reagents were required;
1)Assay Buffer; sodium phosphate 0.1M pH8 .6 . 
containing B.S.A (RIA grade) 0.5% W/V
Sodium azide 0.1% W/V
Normal sheep serum (Guildhay Ltd) 2.0% W/V
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2 ) Standards;
Approximately 15mg 3,3Z,5-triiodo-L-thyronine, free acid 
(Sigma) were dissolved in 4ml of 0.04M NaOH. This solution 
was then diluted 1 in 100 in 0.04M NaOH and it's absorbance 
determined at 325nm. The exact concentration was calculated 
using the formula;
Concentration = QB & 109 nM/L
Molar extinction (E)
Where E 325nm = 4 660 & MW= 651g
This stock was then further diluted into tissue culture 
medium to produce the following standards;
8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06nM/L.
3) Tracer Reagent.
125-I-T3 3mCi/ug 20uCi/ml, (Amersham International pic) 
was typically diluted lin 500 in assay buffer containing 
4mg/ml ANS to give approximately 10,000cpm.
4) Antibody Reagent.
Ovine monoclonal 17C6 anti Tg (Guildhay Antisera Ltd, UK)
was diluted lin 5000 in assay buffer.
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Assay Protocol.
0 .1ml of sample, antibody reagent and tracer were thoroughly 
mixed and incubated for 2 hours at 37°C. Separation was 
achieved by the addition of 0 .2ml donor horse serum 
(Polyclonal Antibodies, Cardiff, UK) and 2 0% PEG (MW = 
20,000). Tubes were vortexed and centrifuged at 3,OOOrpm for 
30 minutes.
Non specific binding (NSB) was determined by replacing the 
antibody reagent with assay buffer. Tubes were decanted and 
counted on a Gamma counter for 60 seconds.
Calculation Of Assay Precision.
In order to assess the reliability of the optimised assay, 
the inter and intra assay coefficients of variance (CV) at 
three levels were determined.
CV was calculated by the following equation;
CV = SD X 100%
X
(Where SD = standard deviation and X = the mean of values).
3.2.9 Enzyme Linked Immunosorbent Assay (ELISA) For The
Determination Of Human IgG.
The following assay was performed to determine whether any 
of the hybrid cell lines secreted human immunoglobulin. 
Previous work by our laboratory and other groups (McLachlan 
et al, 1990) have shown that lymphocytes present within the 
thyroid gland can be immortalised. Many of these thyroid 
infiltrating lymphocytes are potentially autoimmune or
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antitumour in nature (Paschke et al, 1991).
Polystyrene maxisorb microtitre plates (NUNC, Denmark) 
were coated with affinity purified sheep anti human 
antibodies (Guildhay Antisera Ltd) at 2.5ug/ml in 0.1M 
bicarbonate pH9.6 overnight 4°C. Wells were washed two times 
with TBT (Tris-B.S.A-Tween) buffer. 20 Oui of culture 
supernatants and human immunoglobulin standards (Sigma 1- 
500ng/ml Gamma globulins) were incubated in the wells for 60 
minutes at 37°C. After washing with TBT buffer, sheep anti 
human alkaline phosphatase conjugate was applied and 
incubated for 30 minutes at 37°C.
Following a further wash step, PMP substrate reagent was 
added and the colour allowed to develop for 30 minutes. The 
reaction was terminated by the addition of 5Oui 3M NaOH. The 
absorbance was read at 550nm on a Titretek Multiscan Plus 
(ICN FLOW, High Wycombe, UK). Concentrations were then 
determined from a constructed standard curve.
3.2.10 Cell Photography.
Typical examples of the various HTH cell phenotypes were 
cultured for 24 hours at several cell densities in 6ml 
tissue culture plates.
Photographs of these cells were taken with a Nikon FE2 
camera attached to a Nikon 108 phase contrast microscope. An 
Ilford HP5 plus 400ASA film was used (Special thanks to Dr K 
Modha for technical help in the procedure).
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RESPIÆS
3.3.1 £3 Radioimmunoassay & Evaluation.
A highly sensitive T3 radioimmunoassay was constructed 
(Figure 3.2) using a high affinity (2.7 X 1013M) ovine 
monoclonal (Moyle & Overton, 1991). To overcome the 
interference caused by T3 present in the foetal calf serum, 
the ovine monoclonal was utilised at a relatively high 
titer.
Precision and cross reactivity studies (Tables 3.3, 3.4 & 
3.5) revealed a reliable, rapid and highly specific assay 
suitable for the screening of tissue culture supernatants.
3.3.2 An ELISA For The Detection £>f Human Immunoglobulin^
A standard curve for the detection of human immunoglobulin 
in tissue culture medium was constructed (Figure 3.6). The 
proposed assay was evaluated and shown to be specific, very 
reproducibile (Tables 3.7 & 3.8) and highly sensitive with a 
theoretical detection limit of 0.5ng/ml.
3.3.3 Human Thyrocyte Fusion.
Human thyrocytes were fused with two heterohybridoma cell 
lines (HFP3, HFP2A) using polyethylene glycol according to
standard hybridoma methods (Pontecorvo, 1976).
Seven days post fusion very small hybridoma colonies were 
microscopically observed in the 96 well tissue culture 
plates of both fusions. Most of these colonies were clumpy 
hybridomas with classical morphology. However, a few 
fibroblastic colonies with a very granular appearance were 
also present.
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All unfused heterohybridoma cells were now visibly dead 
and the primary thyrocytes were easily distinguishable by 
their limited proliferation, typically 1-2 cell doublings 
(Wynford-Thomas et al, 1990) .
Day 14.
A visual screen of the 96 well tissue culture plates 
revealed 137 positive wells, many containing multiple cell 
colonies. The remaining primary thyroid cells were now 
showing signs of senesence. All the colonies were still very 
small, so initial screening was delayed.
Day 20.
Tissue culture supernatants from the colony forming wells 
were screened for the presence of human thyroglobulin by 
ELISA. 7 fibroblastic colonies had detectable levels of 
thyroglobulin, ranging between 50 & 100ng/ml, but were still 
too small for transfer or cloning.
Day 2JL_
The first hybridoma lines were transfered to 2 4 well 
tissue culture plates and refed with HT medium containing 
20%V/V foetal calf serum, pyruvate and glutamine. Three 
fibroblastic lines were still positive for thyroglobulin 
(100-240ng/ml), but were still too small for cell transfer. 
Day .3-Q-t-
Tissue culture supernatants were removed and screened in a 
batch of assays for the presence of T3, human immunoglobulin 
and thyroglobulin. 6 cell colonies supernatants were found 
to contain detectable levels of human immunoglobulin
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(ranging between 30 & 60ng/ml).
By this stage it had become evident that the HFP2A derived 
fusion lines were unstable. Many of the cell colonies had 
ceased to proliferate and high cell death was observed.
Day 40
Most of the cell lines had now been transfered into 2ml 
well tissue culture plates. The fibroblastic cell lines were 
slower growing than the "hybridoma like" lines and appeared 
much more fragile upon transfer. At low cell densities cell 
doubling slowed dramatically.
The thyroglobulin secreting cell lines had now ceased to 
proliferate, despite cloning and the addition of murine 
spleen feeders.
Day 50.
All the cell colonies from the HFP2A derived fusion were 
now dead. All the lines from the HFP3 derived fusion, 
however still appeared stable and continued to proliferate.
The fibroblastic cell lines were still very fragile and 
would only proliferate in medium containing 20% V/V foetal 
calf serum.
Day 60.
A cell bank was now complete (5 vials of each uncloned 
line) of 70 thyroid derived cell lines. 66 of which had 
classical hybridoma morphology and 4 fibroblastic.
A vial of each batch was thawed and expanded to check 
their recovery.
Table 3.9 summarises the number of cell colonies obtained 
from each fusion and their survival times in continuous 
culture.
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3.3.4 Visual Characteristics Q£ The Hybrid _Cg_ll_ Lingjs^.
Figure 3.10, 3.11, 3.12, 3.13 show typical examples of the 
various hybrid phenotypes. Photographs were taken on a Nikon 
108 phase contrast microscope.
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Table 3 . 3 & cross Reactivity Within. Xhâ 13
Radioimmunoassay
co mp ou nd ACROSS REACTIVITY
D-Triiodothyronine 125
L-Triiodothyronine (T3) 100
Tri-iodoacetic acid 100
D-L Thyroxine 0.4
3'5'5' L-Triiodothyronine (rT3) 0.3
L-Thyroxine (T4) 0.15
D-Thyroxine 0.07
3,5 Diiodothyronine 0.001
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Table 2LA intra M s s x  Precision 01 The. I3 Radicimyncassay^ 
I3 (nMol/L)_ SE m i l  TEBMSInl
1.978 0.107 5.4 14
0.78 0.041 5.2 14
0.083 0.006 8.2 14
Where CV = Coefficient of variation 
SD = Standard Deviation.
Table 3.5 Int*>r assay Precision £f £h£ Z3 RadicilRgmncassay,...
I3 (nMol/Ll SB GV(%1 TERMS (ni
2.3 0.2 8.6 10
0.52 0.05 9.6 10
Where SD = Standard deviation
CV = Coefficient of variation
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Table 3 . 7 Intra Assay Precj-.S-i_Qü fi£ AU fiULSA 
Determination û£ Human lin SC­
HUMAN IgS fng/mlV 52. CV(%I TERMS (ni
489.68 12.446 2.54 16
95.81 4.461 4.64 16
10.12 4.875 4.82 16
Where SD = Standard deviation
CV = Coefficient of variation.
Table 3 . 8 Interassav Precision ££ M  SLIgA XllS
Determination Û£ Human Immunoglobulin.
HDMRN IgG (ng/ml) SB CV(%) TERMS (n).
490.37 13.026 2.7 10
98.33 6.031 6.9 10
10.22 0.601 5.9 10
Where SD = Standard deviation
CV = Coefficient of variation.
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Table 3.9 Summarises The Survival lima ££ Call .CglgnieS. 
Obtained From The Human ThyCocyte Fv§i.Ç>n QyQZ 1 M<?n.thS. In
Continuous Çylfrwre-u
FUSION DAYS CE CONTINUOUS CULTURE.
2 14 14 2Û ££ âa
A 105 111 122 76 63 60
B 24 19 8 3 0 0
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Plate 3.10 Photographs Showing The Vçtyipus, Hybridoma
Morphologies.
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Plate 3.11 Photographes Showing The Various Pyfrridoma
Morphologies .
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DISCUSSION.,
The aim of this study was to utilise heterohybridoma 
technology in an effort to immortalise primary human 
thyroid epithelial cells, with the overall objective of 
producing a stable thyroid cell line.
Normal thyroid epithelial cells were separated and fused 
with 2 different HAT sensitive "Humanised" cell hybridomas, 
termed HFP3 and HFP2A. The fusions were successful in that 
approximately 140 cell colonies were initially obtained, 
from which 70 "stable" lines were derived. All the lines 
derived from the HFP2A fusion appeared unstable and 
eventually failed to proliferate.
Four earlier human thyrocyte fusions using the HFP2A cell 
line also suffered from apparent instability. Typically the 
hybrid cell lines reached confluency in 6 well tissue 
culture plates before hitting crisis. Cloning and/ or the 
addition of murine spleen feeders failed to salvage these 
lines. Chromosome analysis of the two fusion partners may 
help to explain this apparent instability (Chapter 4).,
66 of the "stable" cell lines derived from HFP3 had 
classical hybridoma morphology, although were visually more 
granular than the parental fusion partner.
4 very fragile; slow growing cell lines were also 
generated with fibroblastic characteristics.
Preliminary screening of all the fusion tissue culture 
wells revealed the presence of thyroglobulin in the culture 
media of several colonies. Attempts at cloning these lines 
proved futile and secretion was eventually lost. No T3 was 
detected in any of the hybrids culture media.
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A human immunoglobulin ELISA revealed the presence of 5 
immortalised thyroid infiltrating lymphocytes within the 
fusion. These lines were cloned twice by limiting dilution, 
expanded and cryopreserved for later characterisation. These 
antibody secreting lines could potentially be autoreactive 
in nature.
In summary, the fusion of human thyrocytes by 
heterohybridoma technology has successfully generated 70 
novel cell lines. Initial screening revealed the presence of 
thyroglobulin and human immunoglobulin. Further detailed 
characterisation studies now needed to be performed to 
determine the precise nature and phenotypic characteristics 
of these hybrid lines.
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CHAPTER FOUR.
CHARACTERISATION OF THE HUMAN THYROID DERIVED CELL LINES.
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4.1 INTRODUCTION.
In the last chapter, heterohybridoma technology was 
successfully employed in the production of over 70 novel 
thyroid derived cell lines (hereafter termed HTH).
Preliminary studies on these lines revealed the presence 
of human antibody and thyroglobulin secretion into tissue 
culture supernatants. These characteristics now needed 
further examination.
Other studies were also undertaken to determine their 
phenotypic characteristics. These included TSH-receptor 
stimulation assays, cellular peroxidase determinations, 
Karyotypic analysis, SDS-PAGE studies of proteins expressed 
and cellular proliferation studies.
The results obtained would hopefully enable the 
identification of a thyroid antigen expression cell line 
suitable as a cellular model.
4.2EXPERIMENTAL METHODS^
All Cell culture reagents were obtained from Gibco, 
Paisley, Scotland unless otherwise stated. Chemicals were 
obtained from Sigma, Dorset.
4.2.1 Cell Proliferation Studies♦
In this series of experiments, several of the human 
thyroid derived cell lines (termed HTH) were chosen for cell 
growth studies. Typical lines were compared to the parent 
fusion partner HFP3 under various media conditions. The 
effects of foetal calf serum concentration on cell
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proliferation and antibody production were examined. 
Ultroser HY (Gibco) synthetic media was also examined.
The following cell lines were randomly picked as typical 
examples of the various HTH cell phenotypes;
1) The parent fusion partner, HFP3
2) Human antibody secreting line, HTH37
3) Typical hybridoma morphology line, HTH54
4) Fibroblastic cell line, HTH57
Exponentially growing cells were inoculated into 25ml 
tissue culture flasks (NUNC) containing RPMI-1640 medium 
supplemented with 2mM glutamine, 2mM sodium pyruvate and 
foetal calf serum (2.5, 5, 10 and 20% V/V). Five replicate 
flasks were prepared for each serum concentration. Initial 
cell densities were in the range 1-4 X 104 cells/ml.
Cell growth was monitored at set time intervals by 
counting viable cells with a haemocytometer. The viable cell 
population was distinguised from dead cells by the Trypan 
blue exclusion method (Tenant, 1964). 200ul aliquots of cell 
culture supernatant were also removed from HTH37 flasks and 
assessed for human antibody secretion by the procedures 
described in section 3.2.11.
All the results were expressed with a mean & SEM.
4.2.2 Human Antibody Subclass Dot Blot Assay.
Tissue culture supernatants that were found to be positive 
for human immunoglobulins by ELISA (3.2.9) were pooled and 
saved to allow subclass determination. This was achieved by 
the use of subclass specific monoclonals in a simple dot 
blot assay system (Jefferis et al, 1985).
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2ul of affinity purified anti-human antisera (20ug/ml) 
were dotted onto cellulose nitrate paper (Anderman Scheicher 
& Schuell, W Germany) and allowed to air dry. The paper was 
blocked for 30 minutes with RPMI-1640 medium containing 10% 
V/V foetal calf serum, then washed 3 times with PBSGT. 
Concentrated (10 times) tissue culture supernatants were 
applied to the paper and incubated for 60 minutes at room 
temperature. After washing, human subclass specific murine 
monoclonals (supplied by Dr R Jefferies, Dept Of Immunology, 
University Of Birmingham, UK) were applied and incubated for 
30 minutes. After washing the paper, donkey anti mouse HRPO 
conjugate was applied.
Following a further wash step, bound immunoglobulin was 
visualised by the addition of chromagen (AEC) in 0.1M 
acetate buffer pH5.5 containing 0.04% H202 (Graham, 1965).
4.2.3 Immunohistochemistrv.
To further characterise the human monoclonals, immuno- 
histochemical staining studies were performed on frozen 
sections of human thyroid carcinoma and normal thyroid 
tissue, rat pancreas, gut, adrenal and kidney. Standard 
immunoperoxidase (Heyderman, 1979) and indirect 
immunofluorescence staining techniques (De Silva, 1988) were 
utilised in an attempt to identify the antibody 
specificities.
Briefly, hybridoma culture supernatants were pooled and 
concentrated ten fold using an Amicon Ultrafiltration 
system. Half the subsequent concentrates underwent a 50% 
ammonium sulphate cut (Heytman, 1988) followed by thorough
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dialysis. These samples were then applied to the frozen 
tissue sections.
Bound antibody was detected using anti human peroxidase or 
FITC conjugates.
Fusion partner (HFP3) supernatants treated in the same 
manner were used as control material for non specific 
binding. (Special thanks to Dr M De Silva, NIH, Bethesda, 
Maryland, USA for undertaking these staining procedures).
4.2.4 ELISA Screening Of Monoclonals Against Known
Autoantiaens.
The partially purified monoclonals were run in a range of 
autoimmune antigen ELISA's with appropriate controls to 
determine their specificities. The antibodies were screened 
in the following assays ; thyroglogulin antibody ELISA 
(2.2.7), TSH-Receptor ELISA (5.2.16), TPO, ICA, T4 and T3 
(Guildhay Anti-sera Ltd) .
4.2.5 Determination Qf_ Peroxidase Activity.
A simple enzyme assay was performed to determine whether 
the hybrid cell lines expressed thyroid peroxidase (The 
thyroid microsomal antigen). The method is based on that 
described by Putter & Becker, 1983 and depends on the enzyme 
oxidising the radical cation 2,2'-azino-di-(3-ethyl- 
benzothiazoline-6-sulphonic acid)+ into a stable dye (ABTS). 
All peroxidase activities were expressed in terms of Horse 
Radish Peroxidase (HRPO) units.
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The following reagents were required;
1) ABTS solution (0.02M):
1.Ig ABTS (diammonium salt. Sigma) were dissolved in 100ml 
of 0.067M phosphate buffer pH6.0 (Sorenson; 0.144g Na2HP04 
in 100ml).
2) Peroxide Solution (0.02M).
A 8 .8M commercial solution (BDH Biochemicals) of hydrogen 
peroxide was diluted to prepare a 0.1M stock in de-ionized 
water. This stock was diluted further to 0.02M when 
required.
3) Peroxidase Standards.
Img HRPO (Biozyme, batch 8 98bb, 240 U/mg) was dissolved in 
0.067M phosphate buffer pH 6.0. 0.1ml of this solution was 
then made up to 10ml in a volumetric flask. Various volumes 
of this working stock solution were made up to 2ml in 
phosphate buffer (typically 20,40, 60ul etc).
Note that all the above solutions are not stable long term 
and therefore had to be made freshly.
Sample Preparation.
Confluent 25ml tissue culture flasks (NUNC) of the cell 
lines were harvested and washed 3 times by centrifugation 
(800g 5 minutes). The final cell pellet was resuspended in 
1ml of 0.067M phosphate buffer pH6.0 and the number of cells 
present determined. Subsequently cell concentrations were 
adjusted to 1 X 105cells/ml.
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Cells were lysed by snap freezing in liquid nitrogen 
followed by thawing at room temperature under sonication 
(Ultrawave Ltd, Cardiff, UK). This step was repeated twice 
before samples were run in the enzyme assay.
Assay Protocol
All determinations were carried out in triplicate at 25°C. 
Before starting the assay, all reagents were adjusted to 
25°C. The following were pipetted into a cuvette and 
thorougly mixed;
ABTS solution 0.2ml
H202 0. 2ml
Sample (in phosphate buffer) 0.2ml
The absorbance of each cuvette was read at 405nm at 1 
minute and 6 minutes against a reagent blank (containing 
ABTS and peroxide but no enzyme).
The time between tL minute and 6 minutes after the addition 
of the sample (reaction time =5) was used for calculation. 
The increase in absorbtion of the blank was subtracted. A 
calibration curve constructed will be linear up to 2.0 
absorbance units.
4.2.6 SDS-Polyacrylamide Gel Electrophoresis.
SDS polyacrylamide gel electrophoresis (SDS-PAGE), was 
performed on the cellular proteins present in the 
heterohybridoma cell lines and the human fusion partners, as 
a way to identify novel protein expression.
5% discontinous Tris slab gels were prepared according to 
the general methods of Laemmli (1970), with minor
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modifications to allow better resolution of smaller proteins 
(Thomas, 1978).
The - following buffers and reagents were required;
1) Acrylamide Stock A: 
Acrylamide (BDH, Electran Grade) 
N,NZ- Methylenebisacrylamide
30%W/V 
1.5%W/V
2) Acrylamide Stock B: 
Acrylamide
N,N'-Methylenebisacrylamide
10%W/V 
O'. 5%W/V
3)Electrode Buffer pH8.4 :
Tris-HCl
Glycine
Sodium dodecyl sulphate(SDS) 
Sodium azide
0.05M
0.38M
0.1%W/V
0.1%W/V
4)Sample Buffer:(2X concentrate)
Tris-HCl (pH6.8) 0.02M
Bromophenol Blue 0.02%W/V
2-Mercaptoethanol 20%V/V
Glycerol (BDH Chemicals) 20%V/V
SDS 4%W/V
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Slab gel Preparation.
The separating (lower) gel was prepared as follows;
Acrylamide stock A 8.33ml
Tris-HCl (3M pH8.8) 12.5ml
Water 27.9ml
N,N,N', N-Tetramethylethylenediamine (TEMED) 0.01ml
These were combined and thoroughly mixed. The following were 
then added;
(Note that the ammonium persulphate needed to be freshly 
prepared each time.)
The gel solution was carefully poured into the glass plate 
mould, leaving a 4cm gap at the top. This was then overlayed 
with approximately 5mm of water saturated butan-2-ol and 
left 1 hour for the gel to polymerize.
The butan-2-ol was "washed" from the separating gel using 
a 0.1% SDS solution.
The remaining space in the mould was filled with the 
stacking gel. This was prepared as follows;
Acrylamide stock B 3.0ml
Tris-HCl pH6.8 0.5M 2.4ml
Water 4.4ml
TEMED 0.01ml
These were combined and thoroughly mixed before adding 
SDS (10%W/V) 0.1ml
Ammonium persulphate (10%W/V) 0.1ml
SDS (10W/V)
Ammonium persulphate (10%W/V)
0.25ml
0.25ml
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The plastic comb (for sample wells) was inserted into this 
solution ensuring that no air bubbles were trapped. The gel 
was stored at 4 °C for 24 hours to allow complete 
polymerization and gel "ageing” to occur.
Sample Preparation.
The cell lines for analysis were harvested from confluent 
tissue culture flasks and washed 3 times in RPMI-1640 medium 
by centrifugation (800g 5 minutes).
The cell pellet was "solubilised" by the addition of 40mM 
sodium hydroxide (20Oui) followed by 30 minutes sonication. 
The pH of the sample was adjusted to pH6 .8 by the addition 
of 200ul Tris-HCl (0.5M) pH6.8 .
The protein concentration was estimated by means of a 
bicinchoninic acid (B.C.A) assay (Pierce & Warinner Ltd, 
Chester) using B.S.A as the standard (Smith et al, 1985).
The samples were mixed into the sample buffer and 
denatured by boiling for 2 minutes in a water bath. Samples 
were stored at -20°C until required.
Electrophoresis.
The polymerized gel was clamped into the electrophoresis 
tank, the electrode reservoirs were filled with the 
electrode buffer and then the comb was gently removed. 
lOul of each heat treated sample was applied to the wells 
using a glass syringe. A sample of molecular weight 
standards (Sigma MW SDS 200) was also applied.
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It contained the following protein markers; MW
Carbonic anhydrase 29,000
Albumin, egg 45,000
Albumin, bovine 66,000
Phosphorylase B 97,000
B-Galactosidase 116,000
Myosin 205,000
The gel was electrophoresed at 4 0mA for approximately 6 
hours, until the dye band had almost migrated to the end of 
the apparatus.
The resultant gels were stained overnight in 0.1% W/V 
Coomassie Brilliant Blue (BDH) prepared in fixing solution 
(methanol-acetic acid-water 5:1:5) . The following day, 
destaining solution (5% methanol-7.5% acetic acid V/V in 
water) was applied to the gel in order to visualise the 
protein bands. Typically 2-3 changes of destain were 
required to obtain a "stain free background."
Immunoblottina Studies.
Immunoblotting of the gels cellular proteins with 10 
Graves patient sera were carried out according to standard 
methods (Garfin & Bers, 1989). (Special thanks to Dr G,N 
Cowdrey, Dept Of Biochemistry, Hurstwood Park, Haywards 
Heath for his technical assistance in these procedures).
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4.2.7 Karyotyping Study Of The Cell Lines.
Karyotype analysis of the fusion partners (HEP3, HFP2A) 
and the thyroid derived cells (HTH) were performed by 
conventional techniques (Lin et al, 1977) . these were as 
follows;
1) The cells undergoing karyotypic analyses were cultured at 
4-5 X 106 cells/ml in RPMI-1640 medium containing 20% V/V 
foetal calf serum, pyruvate and glutamine.
2) Cell division (mitosis) was arrested in metaphase by the 
addition of 2.5ug/ml demecolcine (Gibco, Scotland) to the 
media for 120 minutes 37°C.
3) The cells were harvested from the tissue culture flasks 
and were pelleted at 1 0 0 0rpm for 4 minutes in 2 5ml 
universels (Sterilin).
4) The cell pellets were resuspended in 10ml of 0.075M KC1 
and incubated for 10 minutes prior to centrifugation 
(lOOOrpm, 5 minutes).
5) The cell pellets were gently resuspended in 10ml of 
fixing media (methanol : glacial acetic acid 3:1 V/V) and 
were incubated at 4°C for 10 minutes. (Note the fixing media 
should be stored at -20°C.)
6) The cells were pelleted and refixed (step 5) before 
finally being resuspended in 1ml of fixer. Suspensions were 
then stored overnight.
7) Chromosome spreads were prepared using a glass pasteur 
pipette to drop the cell suspension onto clean acid washed 
glass slides. Typically two droplets were allowed to fall 
60cm onto each slide, before being allowed to air dry.
Evaporation of the fixer causes the cells to rupture,
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allowing the released chromosomes to adhere to the slide.
8) For chromosome banding, the spreads were digested with 
trypsin (lmg/ml ICN FLOW, High Wycombe, UK) in phosphate 
buffered saline (PBS pH7.4) for 60 seconds.
9) Chromosomes were visualised by staining slides for 40 
seconds in a mixture of Giemsa stain : Sorensons buffer 
(1:1V/V). Excess stain was washed away using distilled water 
and allowed to air dry.
4.2.8 Cyclic AMP Stimulation Bioassays.
It has been widely reported that.intracellular and 
extracellular cAMP levels are transiently raised following 
TSH stimulation in thyrocytes (Kraiem et al,1990).
To determine whether the hybrid cell lines developed 
contained an active receptor-adenylate cyclase complex, the 
following bioassay was prepared.
Methods.
All experiments were performed in triplicate. The cell 
lines were plated out to a density of 3xl05/ml over 6 well 
tissue culture plates (NUNC, Denmark) in RPMI-1640 medium 
containing 10% V/V foetal calf serum, 2mM pyruvate and 2mM 
glutamine. Fusion partners HFP3, HFP2A and SP2 were used as 
control cells and were thus treated similarly. Following an 
overnight incubation, the existing media was carefully 
removed and replaced with 3ml/well of fresh medium, 
containing 0.5mM l-methyl-3-isobutylxanthine in the presence 
or absence of 50mU/ml human TSH (kindly donated by Lyn 
Calder, Amersham International).
At the end of a 2 hour incubation period, cAMP levels in
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the media were assessed by the acetylated RIA described 
below and levels accumulated within the cells were 
determined by the standard RIA. Both methods are 
modifications of the procedures described by Cailla et al, 
1973, 1975. Special thanks to Dr Peter Woods, Southhampton 
General Hospital for advice on setting up these assays.
Non-Acetylation cAMP RIA.
The following reagents were required;
1) Assay buffer : Tris-HCl 50mM pH7.4
containing EDTA 5mM
B.S.A (RIA grade) 0.5%W/V
Sodium azide 0.01%W/V
Isobuty1-1-methyIxanthine 0.5mM
2)Standards;
A 10uM/L stock standard of cyclic AMP (Sigma) was prepared 
in distilled water and stored in 0.5ml aliquots at -20°C. 
Tissue culture medium standards (0.16-2OpM/tube) were 
prepared directly from this stock.
3) Antiserum reagent;
Rabbit anti-cyclic AMP polyclonal antisera (Chemicon 
International INC, Temecula, USA) was diluted 1 in 100,000 
in the above assay buffer.
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4) Tracer Reagent;
Adenosine 3z,5z-cyclic phosphoric acid (125-I) 2z-0-
succinyl (iodotyrosine methyl ester) was diluted 1 in 25 in 
the assay buffer (Dupont, Stevenage, UK). This dilution 
typically gave 20,OOOcpm/lOOul ie approximately lOnCi/tube.
Assay Protocol »,
0 .1ml of sample, antiserum reagent and tracer reagent were 
thoroughly mixed and incubated overnight at 4°C. Separation 
was achieved by the addition of 0 .1ml donor horse serum 
(Polyclonal Antibodies, Cardiff, UK) and 0.8ml 20% PEG 
(20 , 0 0 Omw) . The tubes were vortexed and centrifuged 
(SOOOrpm, 30 minutes). Tubes were decanted and counted for 
60 seconds.
cAMP Acétylation Assay.
The following reagents were required;
1) Assay buffer: sodium acetate 50mM pH6.2
2) Standards: Stock standard (10uM/L) was diluted into 
tissue culture medium to give the working range (2 - 
0.03pM/tube).
3) Antiserum reagent; Rabbit anti-cyclic AMP polyclonal 
antisera was diluted 1 in 150,000 in the above assay buffer.
4) Tracer; As for the non acétylation assay, but diluted in 
acetate buffer.
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Assay Protocol.
Standards or tests were acetylated at 4°C by the addition 
of 5ul of a 2:1 V/V mixture of triethylamine : acetic
anhydrvâe. This reaction must be carried out in glass LP4 
tubes whilst being vortexed.
The acetylated sample was thoroughly mixed with 0.1ml 
antiserum reagent and tracer reagent and incubated overnight 
at 4°C. Separation of bound tracer was achieved by the 
addition of 0.1ml donor horse serum and 80Oui 20% PEG (mw 
20,000). Tubes were vortexed and centrifuged at 3,000 rpm 
for 30 minutes. Tubes were decanted and counted for 60 
seconds.
Evaluation Of Cyclic AMP Radioimmunoassays.
Determination Of Theoretical Detection Limit.
20 replicate samples of cyclic AMP "free" media were assayed 
according to the general assay protocols. The results 
obtained were utilised in the following equation;
Minimum detection limit =3 X S.D of replicate blank.
Within Batch Precision Of The cAMP Assay.
A within batch precision study was performed on three media 
pools using the standard assay protocol. 20 replicates 
assays of each media pool were carried out in a 24 hour 
period and the results obtained were used to calculate the 
imprecision.
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Between Day Precision Of The cAMP Assay.
Calibration curves were produced over a 10 day period to 
determine the reproducibility of the assay. Serum pools were 
prepared containing three levels of cAMP. Aliquots of these 
were stored at -20°C until required.
Cross Reactivity Study.
The specificity of the assay system was assessed by 
measuring apparent cAMP response caused by high levels of 
various potentially cross-reactive analytes. The following 
were screened according to the standard assay methodology; 
Adenosine 5'-triphosphate ■ (ATP)
Adenosine-5- diphosphate (ADP)
Cytidine 3-5-cyclic monophosphate (cCMP)
Guanosine 3',5'-cyclic monophosphate (cGMP)
Inosine 3',5'-cyclic monophosphate (cIMP)
4.2.9 TSH Binding Assay.
A radioligand binding assay was performed to determine 
whether the hybrid cell lines expressed TSH receptor. The 
method was a modification of the procedures described by 
Karsenty et al, 1985 and Taylor et al, 1990.
The following reagents were used;
1) Assay buffer (TNB) pH7.4, containing 
Tris-HCl lOmM
NaCl 50mM
B.S.A (RIA grade) 0.1%W/V
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2) Tracer Reagent.
1 2 5 j labelled human TSH, specific activity 79uCi/ug, 
2.lug/ml (kindly donated by Lyn Calder, Amersham 
International) was diluted in TNB buffer to give 50, 000cpm 
per lOOul.
All experiments were performed in triplicate at 37°C. 
Cells were harvested from tissue culture flasks (NUNC, 
Roskilde, Denmark) and were washed 2 times by centrifugation 
(800g, 3 minutes) in warm RPMI-1640 medium. The cells were 
resuspended in TNB buffer, counted and used imme idiately.
400ul of resuspended cells (1 X 106 cells per tube) were 
incubated with 10Oui of tracer reagent in the presence or 
absence of "cold" bTSH (1000mU/ml) for 1 hour.
To determine the amount of non specific binding cell 
lines, HFP3, HFP2A, SP2 (EACC PHLS Porton Down, UK), RINmSF 
(clonal rat insulinoma cell line; Gazdor et al,1980) were 
used as controls.
Following incubation, the cells were washed once by the 
addition of 2ml TNB buffer and centrifuged at 800g for 3 
minutes. Finally the assay tubes were counted for 60 seconds 
in a gamma counter (LKB Instruments, Croydon UK) to 
determine the amount of bound radioactivity.
4.2.10 Iodide Uptake Study On Thyroid Derived Cell Lines♦
Normal thyrocytes in primary culture and many thyroid cell 
lines have the ability to accumulate iodide in the presence/ 
absence of TSH (Bidley et al, 1988).
Iodide uptake was determined in triplicate cultures 
according to the methods of Beere et al, 1990 and Karsenty
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et al, 1985. The anti thyroid drug methimazole was added to 
the assay medium to inhibit any possible iodide release from 
the cells.
Experimental procedure..
The thyroid derived cell lines were plated out to a 
density of 3 X 105/ml in 6 well plates (NUNC) for 2 days in 
RPMI-164 0 medium containing 10% V/V foetal calf serum, 2mM 
pyruvate, 2mM glutamine and bTSH (20mU/L). The cell lines 
HFP3, HFP2A and SP2 were used as assay controls.
On the day of assay, the media were carefully removed and 
the cells washed twice with RPMI-1640. 5ml of RPMI-1640 
containing 0.2mCi Nal/L (Amersham International) and 3mM 
methimazole (Sigma) were applied to each well and incubated 
for 90 minutes at 37°C. Following the incubation, the media 
were carefully aspirated and the cells washed with RPMI-1640 
to remove non specific iodide binding.
Cells were "solubilised" by the addition of 1ml lOOmM 
NaOH. After a 5 minute period of gentle mixing, 4 x lOOul 
aliquots were taken and the radioactivity determined for 60 
seconds.
To determine the amount of iodide organically bound 1ml of 
40% W/V trichloroacetic acid (BDH, Poole, UK) was added to 
each tube. The protein precipitated was centrifuged at 
3,00Orpm for 30 minutes. After decanting the pellet was 
counted for 60 seconds.
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4.3RESULTS .
4.3.1 Cell Proliferation Studies.
Several cell lines randomly picked as typical examples of 
the various HTH cell phenotypes were grown under various 
media conditions. The growth curves are shown in Figures 
4.1-4.4. The following observations were also noted;
1) The reduction of foetal calf serum in the cell media 
caused a decrease in the cell doubling time.
2) The fibroblastic line HTH57 was found to be very fragile, 
only proliferating in media enriched with 20% V/V foetal 
calf serum.
3) Cell adhesion to the flasks was reduced with lower serum 
concentrations. At 2.5% the cell lines HTH37 and HTH 54 
showed very high cell death at low cell densities and very 
poor adhesion properties.
4) All the HTH lines were observed to have slower doubling 
times than the parental fusion partners. The fibroblastic 
cell line HTH57 struggled to proliferate at low cell 
densities and had the slowest cell doubling time.
5) Human antibody secretion from HTH37 was observed to be at 
it's peak with high cell densities and little cell division. 
At 2.5% serum no antibody secretion was detected.(Figure 
4.5).
6) None of the cell lines studied were able to proliferate in 
Ultroser HY, the synthetic defined medium.
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4.3.2 Characterisation Of The Human Monoclonal Antibodies. 
The immunoglobulin subclasses of the thyroid derived human
monoclonals were determined by a simple dot blot assay 
system. The results obtained are presented in Table 4.6.
4.3.3 Immunohistochemical Studies.
The purified human monoclonal antibodies derived from the 
human thyroid underwent immunoperox i das e and 
immunofluo*'£5o2/><32^  studies on various tissue sections. The 
following tissues were examined; human thyroid (normal & 
carcinoma) rat pancreas, gut adrenal and kidney. No binding 
above that of the control was observed with any of the 
monoclonals.
4.3.4 ELISA Autoantiaen Studies.
No binding was found to the following known.autoantigens; 
ICA, ICSA, TPO, Tg, TSH receptor. Insulin T3 and T4.
4.3.5 Peroxidase Activity Determination.
The peroxidase activity within the cell lines were 
determined and compared to the parent fusion partner HFP3. 
The activities were calculated from a constructed standard 
curve (Figure 4.7), and expressed in terms of HRPO unit 
equivalents.
Peroxidase activities were significantly higher in the 
fibroblastic cell lines than the fusion partner HFP3. (Table 
4.8).
114
4.3.6 Cyclic AMP Radioimmunoassays.
Two radioimmunoassays standard curves were constructed 
which would allow the determination of cAMP in an assay 
biosystem (Figures 4.9, 4.10).
The assays were evaluated for assay precision and cross 
reactivity. The results are presented in Tables 4.11, 4.12 
and 4.13.
The Theoretical Detection Limit ûf Acétylation Assay.,
10 replicate samples of cAMP free media were assessed by 
the standard assay procedure. The detection limit was 
calculated to be 45fmol/tube, as determined by the 
concentration which is 2 standard deviations above the zero 
standard.
4.3.7 SDS PAGE Studies.
SDS PAGE was performed on the cellular proteins present in 
the heterohybridomas and fusion partners as a way of 
identifying novel protein expression. An example of a 
protein profile in typical HTH cell lines is shown in 
plates 4.14 & 4.15.
It can be noted that the fusion partners (HFP3, HFP2A) and 
the "hybridoma " morphology HTH cell lines expressed the 
same proteins.
The fibroblastic lines expressed several novel proteins 
with a broad range of molecular weights.The most intense 
"banding" observed around the 60 to 80 KDa region.
Immunobloting of these fibroblastic lines (HTH57) from the 
gels onto nitrocellulose gave a very faint band around 
7 OKda, when Graves sample 1914 2 was used. All other
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autoimmune sera examined failed to bind.
4.3.8- cAMP Bioassays.
Intracellular and extracellular cAMP levels were the same 
in all the lines examined. Addition of TSH failed to 
stimulate a response, suggesting the lack of a TSH receptor- 
adenylate cyclase complex in the HTH lines.
4.3.9 TSH Binding £  Iodide Uptake. ;
None of the heterohybridoma cells were observed to
accumulate iodide or bind TSH specifically.
4.3.10 Karyotypic Analysis.
To confirm whether the HAT resistant cell lines derived 
from the thyroid fusion were human heterohybridomas, 
karyotypic analysis studies were performed.
10 cell lines (HTH) were compared with the karyotypes of 
SP2, HFP2A and HFP3 (Table 4.16).
The karyotype "spreads" of SP2 and HFP2A revealed the 
presence of chromosomes that were acrocentric (the 
centromere very near to the end of the chromosome), which 
are characteristics typical o f  a murine origin.
The chromosome spreads of the successful fusion partner 
HFP3, demonstrated the presence of several metacentric 
chromosomes (centromere is located near the midpoint of the 
chromosome), implying a human origin.
Karyotype analysis of the human antibody secreting lines 
(HTH 15, 25, 37) revealed the presence of metcteentric and
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submetacentric chromosomes typical of a human karyotype, 
with an average chromosome number of 46. There was no 
obvious presence of murine DNA.
Chromosome spreads of the fibroblastic lines (HTH57, 60) 
and the remaining hybridomas exhibited the presence of both 
acrocentric and metacentric chromosomes consistent with the 
hybrid nature of these lines.
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Table 4.6 Immunoglobulin subclasses the human monoclonal
antibodies.
NAME QE. CELL LINE Ifl CL&SS SECRETED LIGHT CHAIN
HTH15E2 IgGl KAPPA
HTH25G7 IgGl N.D
HTH37B1 IgG2 LAMBDA
HTH57A1 IgGl KAPPA
Where N.D = not determined
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Table 4.8 Peroxidase activities in the cell lines, expressed
in HRPO unit equivalents.
CELT, LINE MEAN ACTIVITY TERMS iûl
(U/min/105cells)
HTH57
i—io 0.020 6
HTH58 0.19 0.013 3
HTH4 6 0.26 0.019 3
HTH62 0.24 0.021 6
HFP3 0.11 0.027 6
HFP2A 0.10 0.015 6
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Table 4.11 & cross reactivity ttitlÛP tilÊ cyclic ÂME
assay.
COMPOUND ^CROSS-REACTIVITY
Cyclic AMP 100
Cyclic GMP 0.0018
Cyclic IMP 0.0002
Cyclic CMP 0.0006
ATP 0.0002
ADP 0.0001
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Table 4.12 Intra assay precision fi£ fchfi cyclic jàME Assay.,. 
Cyclic AMP Mean (fmol/tube) 5*12. C»V(%) Terms (n)
12.01 0.606 5.02 10
340 15.02 4.40 10
1510 110 7.20 10
where C.V = coefficient of variation 
S.D = standard deviation.
Table 4 .13 intra a g gay pra.cialaa af the nan acetyl.at..ed
cyclic assay.,.
Cyclic AMP (pmol/tube) S,D CiV(%). TarmS-ÜÜ.
1.535 7.4 10
0.232 4.5 10
0.063 6.3 10
where C.V = coefficient of variation 
S.D = standard deviation.
20.55
5.08
0.98
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Table- 4.16 Karvotvpic Analysis ££ Several Selaclad BIfl Call
Lines.
CELL LINE NUMBER QSL DETERMINATIONS CHROMOSOMES (meaill
SP2 (murine fusion partner) 10 40
HFP2A 10 40, 80
HFP3 10 43, 86
HTH10 8 63
HTH15 12 46
HTH20 9 74
HTH25 6 45
HTH30 10 82
HTH37 8 46
HTH40 10 74
HTH50 12 82
HTH57 15 63
HTH60 12 86
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4.4 DISCUSSION.
In this chapter the various HAT resistant cell lines 
obtained from the human thyroid fusion were subjected to a 
range of screening assays in order to determine their 
phenotypic characteristics.
Karyotypic analysis revealed the presence of several 
metacentric and submetacentric chromosomes in the (HTH) 
heterohybridoma cell lines, confirming their human origin. 
Interestingly the human antibody secreting lines (HTH37, 
15) appeared to have a "normal" human karyotype with no 
obvious presence of murine DNA. This is in broad agreement 
with the work of De Silva et al, 19 91 using the first 
generation heterohybridoma fusion partner HMY on peripheral 
blood lymphocytes obtained from a insulin dependent diabetic 
patient. This maybe due to the presence of a latent DNA 
virus present in the fusion line imparting immortalisation 
or, more likely murine DNA being translocated onto the human 
chromosomes.
The novel HTH lines and fusion partners were screened for 
possible EBV and mycoplasma infection by commercial methods 
( ICN FLOW, High Wycombe, UK & Imperial Laboratories, 
Andover,UK) and proved negative
The fibroblastic lines (HTH57, 60) and the remaining
"hybridoma" lines revealed a mixed karyotype, typical of 
heterohybridoma cells (Tan et al, 1984; Tucker et al, 1981; 
Richards et al,1992; Sugiyama et al, 1991).
Growth and proliferation studies on the selected HTH cells 
showed that their cell doubling time to be longer than the
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parental fusion partner HFP3 (Figures 4 .1-4.4), further 
supporting their hybrid nature. The fibroblastic lines were 
found to be extremely "fragile" being sensitive to media 
conditions and cell density, making cell cloning difficult. 
They were only able to proliferate in media containing 20% 
V/V foetal calf serum.
Noneof the cell lines however, were able to proliferate in 
the synthetic defined media (Ultroser HY)
The antibody secreting lines were stable in a broad range 
of media and were capable of constant antibody secretion. 
Antibody production was similar in all the serum media 
concentrations studied (Figure 4.5).
It was observed to be highest in the early exponential 
phase and during the onset of the decline phase. This 
apparent increase in antibody production during entry into 
decline phase has been postulated to be due to the release 
of accumulated intracellular antibody from dying cells 
(Emery & Al-Rubeai, 1990).
The human monoclonals produced were subclassed, but 
immunohistochemical staining studies failed to identify 
their specificities (target antigen). These human antibodies 
may be anti-tumour in origin, but due to the lack of primary 
patient tissue, this could not be investigated.
Screening the HTH cell lines for common thyrocyte 
characteristics such as iodide uptake, cAMP stimulation and 
TSH binding all proved negative.The fibroblastic lines 
however, did visually look like primary thyrocytes and had 
cellular peroxidase activity.
SDS-PAGE studies on the cellular proteins in the HTH lines
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strongly suggested that all the "hybridoma" morphology cell 
lines had a lymphocytic protein expression. This maybe due 
to the thyrocyte DNA failing to express itself in the hybrid 
construct, or alternatively the cell lines are actually 
derived from lymphocytes present in the thyroid.
SDS-PAGE of the fibroblastic lines revealed the presence 
of several novel proteins. Immunoblotting of these proteins 
with Graves' antisera weakly identified a VOKda protein. 
This protein however, was only identified by one patient 
sample and therefore seems unlikely to be a "common" 
autoantigen. It may possibly be a heat shock protein 
(Heufelder et al,1992).
Surprisingly no band appeared around lOOKda region of the 
gel, suggesting the peroxidase activity might not be due to 
TPO. The activity may be connected with an increase in the 
expression of the lymphocyte peroxidase within the 
heterohybridoma constructs.
Therefore in summary, the human thyroid heterohybridoma 
fusion produced 70 novel humanised cell lines with three 
basic cell phenotypes. These are;
1) Immortalised thyroid infiltrating lymphocytes.
2) Mixed karyotype hybridoma cells, lymphocyte in nature.
3) Fibroblastic cells.
Only the fibroblastic lines appeared to show any thyrocyte 
phenotypic characteristics. However, their lack of common 
thyroid antigens (TSH receptor, Tg and TPO), made them 
unsuitable as a human thyrocyte models.
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CHAPTER 5l
DEVELOPMENT OF AN ELISA FOR THE MEASUREMENT OF TSH 
RECEPTOR AUTO-ANTIBODIES.
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5 .1. GENERAL INTRODUCTION..
Immunoglobulins which interact with the TSH receptor can 
be detected in all the autoimmune thyroid diseases, namely 
Graves' disease and it's variants, Hashimoto's disease and 
myxoedema (Williams & Goodburn, 1983). These autoantibodies 
are capable of interacting with the TSH receptor or a 
closely related site, and of either mimicking the action of 
TSH action leading to ^pe*thyroidism, or blocking TSH action 
with consequent hypothyroidism (Filletti et al, 1991; Hall 
et al, 1982: Kasagi et al, 1990).
Detection of these autoantibodies is of clinical value in 
the diagnosis of Graves' disease and it's variants, in 
predicting the risk of neonatal hyperthyroidism or 
hypothyroidism and in predicting relapse after anti thyroid 
drug therapy ( such as carbimazole or methimazole) (Harrison
6 Leedman, 1990; Saski et al, 1988).
5.1.1 Assays For TSH Receptor Autoantibodies.
There are at present two basic assay formats for the 
measurement of TSH receptor antibodies;
1) Bioassays which allow the measurement of antibodies that 
react with the receptor in a stimulatory manner (TSAb). 
These types of assay depend on the induction of a biological 
response, such as cAMP generation in cultured thyroid cells 
(Kohn et al, 1986; Vitti et al, 1982; Hinds et al, 1981; 
Davies et al, 1983). They tend to be laborious, technically 
difficult and unreliable for routine clinical screening.
The second type of assay measures antibodies that bind to 
the receptor and compete with TSH for binding. These
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"inhibition" assays measure both stimulatory and inhibitory 
antibodies without discrimination, since both types of 
antibody may be present in the same patient sample (Kraiem 
et al, 1990; Rootwelt, 1983).
Existing commercial assays for TSH receptor autoantibodies 
(TBI) are all radioreceptor assays. They are based on the 
ability of TSH receptor antibodies to inhibit the binding of 
125-I-bTSH tracer to detergent solubilised porcine receptors 
(Southgate et al,1984; Humphries et al,1982).
These assays have several limitations;
1) The TSH receptors are inherently unstable unless frozen 
at -7 0 °C or freeze dried. Furthermore, once thawed/ 
reconstituted they only have a shelf life of 24 hours.
2) The assay requires the use of expensive equipment, 
potentially hazardous materials (125I) and is laborious to 
run on a large scale.
3) The bTSH tracer having been "receptor purified" on crude 
thyroid membranes has poor stability (14 days) and varies 
greatly from batch to batch.
4) The use of porcine receptors with bovine TSH tracer to 
measure human autoantibodies is not an ideal system, since 
many people contain native anti-species antibodies (Gosling, 
1990; Wickus et al, 1991).
Non Isotopic Assays For TSH Receptor Autoantibodies.
In this chapter the possibility of developing a 
nonisotopic assay for the measurement of TSH receptor 
antibodies was investigated.
Previously a dot immunobinding assay (DIBA) on
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nitrocellulose filters (Bako et al, 1987, 1989) and an
indirect ELISA (Chang & Liaw, 1988) for TSH receptor 
antibodies have been reported. Both these assays however, 
were unspecific due to the presence of thyroglobulin in the 
receptor preparation. For these reasons, a non-isotopic 
screening method (ELISA) which would be specific, cheap, 
robust and simple to run was developed.
The initial work in this study concentrated on the partial 
purification and stabilisation of the active receptor within 
the existing radioreceptor assay. This background research 
then allowed the development of an ELISA for TRAb. The 
possibility of a competitive and an indirect ELISA were 
examined in three formats (Figure 5.0).
The competitive ELISA would depend on the direct 
inhibition of an enzyme labelled TSH conjugate by sample 
autoantibodies for a limited number of receptors immobilised 
onto polystyrene microtitre plates. Following a wash and 
substrate stage, the displacement of conjugate would 
produce a proportional displacement in colour product 
formation.
The second possible format would be the chemical labelling 
of TSH with FITC or biotin, which could then be used as an 
amplification stage with the use of a sheep anti-label 
alkaline phosphatase conjugate .
The indirect ELISA system would depend on the TSH receptor 
autoantibodies binding specifically to immobilised 
receptors. Following a wash stage, the bound antibodies 
would be detected by the addition of a sheep anti human IgG 
alkaline phosphatase conjugate.
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The final aim of this study was to replace the porcine 
receptor with a one from a cloned human cell line. However, 
since, the TSH receptor was not expressed (Chapter 3, 4) this 
target proved impossible.
5.2 EXPERIMENTAL METHODS-
All reagents were obtained from Sigma Chemicals, Dorset, 
UK unless otherwise stated in the text.
5.2.1 Preparation and Solubilisation Of Porcine Thyroid
Membranes.
The following procedure is based on the methods of Rees 
Smith and Hall, 1981 and Southgate et al, 1984 with a few 
minor modifications;
All stages of preparative work were carried out at 4°C.
1) Fresh porcine thyroids were obtained from the local 
abattoir and stored in phosphate buffered saline (PBS) 
pH7.4.
2 )In the laboratory, excess connective tissue was removed 
and then they were individually snap frozen at -70°C.
3) On the day of preparation, the tissue was thawed, cut 
into small pieces and mixed with Tris-HCl pH7.0 containing 
lOmM benzamidine and 0.1% W/V sodium azide (1:3 W/V ratio).
4) The mixture was homogenised for 8 X 1 0  second bursts in a 
Potter S homogeniser (Braun, West Germany).
5) The resultant homogenate was forced through a course 
cooking sieve (R, Dyas, Guildford) with a large round backed 
spatula.
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6 ) The liquid obtained, was centrifuged at 80Og for 10 
minutes (4.2 rotor, 1500rpm on a Beckman centrifuge) to 
remove large cellular debris.
7) The pellet was discarded and the supernatant centrifuged 
at 15,000g (12,OOOrpm J17 rotor) for 30 minutes.
8) The supernatant was carefully decanted off the membrane 
pellet. The membranes were then solubilised with 1% V/V 
Triton X100 (Aldrich Chemicals, Gillingham,UK) in the above 
Tris buffer (Ig original tissue/ml solubilisation buffer) 
for 1 hour. The solution was gently mixed by means of a 
pasteur pipette ensuring not to foam the mixture.
9) The solubilised membrane preparation was then centrifuged 
at 15,000g for 45 minutes (12,OOOrpm J17).
10) The supernatant was carefully removed with a pasteur 
pipette and finally centrifuged at 100,000g for 1 hour 4°C 
(65TY rotor, 40,OOOrpm, Beckman Ultracentrifuge 1-15).
11) The resultant clear and lipid rich (top) fractions were 
saved, aliquoted and stored at -70°C until required. The 
pellet was discarded.
5.2.2 Todination And Purification QjL TSH Tracer.
The procedure below is based on that described by Dawes et 
al, 1978, Greenwood et al, 1963 and Goldfine et al, 1974 
with minor modifications. The methods were used to iodinate 
both human and bovine TSH.
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Actual Todination Initial Purification.
The following reagents were pipetted and gently mixed at 
room temperature in a 1.5ml eppendorf tube (ICN FLOW 
Laboratories, High Wycombe, Bucks, UK);
50ul TSH (20mU human/1U bovine TSH, Bioproducts, Belguim) 
50ul lodination buffer (0.05M sodium phosphate pH7.4)
5ul Sodium iodide-125 (0.5mCi Amersham International)
The reaction was started by the addition of 5Oui of 
chloromine T (BDH Biochemicals Ltd, Poole, UK) in iodination 
buffer (lmg/ml. Sigma Chemicals). After 20 seconds gentle 
mixing the reaction was terminated with the addition of 50ul 
of freshly prepared sodium metabisulphate (lmg/ml) in 
iodination buffer.
The iodinated TSH was separated from aggregates and free 
iodide by gel filtration. A 30 x 1.5ml Sephacryl S300 column 
(Pharmacia LKB) was set up and pre-equilibrated with 
iodination buffer containing 1% W/V B.S.A.
The iodination mixture was applied to the column and 0.5ml 
x 120 tubes were collected overnight (0.25ml/minute flow 
rate) at room temperature. lOul aliquots were taken and were 
counted for 60 seconds on a gamma counter. The radioactive 
peaks were pooled.
Receptor Purification Of The TSH Tracer.
All preparative stages of the thyroid membrane preparation 
was undertaken at 4°C.
Fresh porcine thyroids obtained from the local abattoir 
were homogenised and strained according to the methods
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described in 5.2.1. The resultant suspension was spun at 
800g (4.2 Beckman rotor, ISOOrpm) for 10 minutes to remove 
large-tissue and cell debris.
The supernatant fraction was collected and further 
centrifuged at 15,0 0 Og for 30 minutes to pellet the 
membranes. The pooled TSH tracer peak was applied to the 
membrane pellet and gently mixed using a pasteur pipette. 
The mixture was then incubated in a water bath for 25 
minutes at 3 0 °C to allow the tracer to bind to the 
receptors.
Bound tracer was separated from free by centrifugation at 
20,000g for 15 minutes. The resultant pellet was resuspended 
in 8ml of ice cold 50mM Tris-HCl pH7.4 containing 2M NaCl. 
After 30 minutes incubation at 4°C with intermittcxnt mixing 
the solution was centrifuged at 20,000g for 30 minutes and 
the subsequent supernatant collected.
This receptor "purified" tracer was applied to a Sephacryl 
S300 gel filtration column (1.5 x30cm) pre-equilibrated with 
iodination buffer containing 1% W/V B.S.A and 25mM sucrose. 
0 .5ml x 1 0 0ml fractions were collected (flow rate 
O .2ml/minute> and counted in a gamma counter. The 
radioactive peak obtained was pooled, 0 .2udiam sterile 
filtered, aliquoted, lyophilised and stored at 40C.
5.2.3 TSH Receptor Displacement Assay (TRAB).
The following assay was used to assess porcine receptor 
purification strategies at the various stages of ELISA 
development. The assay was also necessary for the validation 
of the final proposed ELISA.
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The following reagents were required;
1) Assay Buffer pH7.4
Tris-HCl 0.05M
B.S.A (RIA grade) 0.1% W/V
Sodium azide 0.1% W/V
2)Receptor purified bovine TSH tracer
(Typically 3nCi iodine-125-bTSH per 4ml vial, RSR Cardiff or 
prepared by the methods 5.2.2).
3) Standards;
Bovine TSH (Sigma Chemicals) diluted into normal pooled 
serum over the range 0-5mU/ml was used for standards. The 
bovine TSH standards were then calibrated against the MRC 
LATS B control (National Institute for Biological Standards 
and Controls, Hampstead, London).
In the assessment of receptor purification strategies, bTSH 
prepared in the appropriate buffer was used (+ 0.5%W/V 
B.S.A) .
Assay Protocol.
50ul sample, 200ul assay buffer, 50ul porcine receptor 
preparation and 5Oui tracer were thoroughly mixed and 
incubated for 1 hour at 37°C (alternatively 4°C overnight). 
Non specific binding (NSB) of serum to the tracer was 
determined by replacing the receptor preparation with assay 
buffer.
The separation of bound tracer was achieved by the addition
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of 500ul (3mg/ml) carrier IgG (Sigma fraction 1,2) and 1ml 
30% W/V polyethylene glycol (mw= 4,000) in 1M NaCl. The 
tubes were vortexed and centrifuged at 3,00Orpm for 30 
minutes at 4°C.
The tubes were decanted/ aspirated and counted on a gamma 
counter for 60 seconds. Background and NSB counts were 
subtracted from all the samples and the results expressed as 
a percentage of counts bound in the zero tubes :
counts bound in presence e£ sample x 100 
Counts bound at zero TSH concentration
Typically if 10,OOOcpm were added , zero binding would be 
45% and non specific binding around 10%.
5.2.4The Effect Of Protease Inhibitors On TSH Receptor
Stability.
Purification of the TSH receptor from thyroid membranes 
has always been difficult due to it's labile nature. To 
overcome these problems several groups have used a 
"cocktail" of protease inhibitors to limit the rate of 
protein degradation (Akamizu et al, 1988; lida et al, 1987; 
Islam & Farid,1985).
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In this experiment the following enzyme inhibitors were 
examined individually; (All inhibitors were obtained from 
Sigma unless otherwise stated).
Working Concentration 
Chymostatin 0.5ug/ml
Leupeptin 0.lug/ml
Bestatin 0.lug/ml
Phenylmethyl sulphonyl fluoride (PMSF) 0.3mM
Aprotinin 250U/ml
Glycerol (BDH Biochemicals) 40% V/V
1) A freshly thawed solubilised porcine thyroid receptor 
preparation was divided into 2ml aliquots and stored at 4°C 
in LP4 tubes.
2) To each tube, 1ml of the various inhibitors were added. 
These were prepared at 3 times their working concentration 
in Tris-HCl pH7.0 to account for dilution effects. Duplicate 
tubes were prepared for each inhibitor.
3) At set time intervals, 50ul aliquots (duplicate) were 
removed from the LP4 stocks and assessed for bTSH binding 
activity according to the general methods described in 5.2.3
Control tubes were set up at each time interval with a 
fresh receptor preparation to determine "normal" binding 
activity. The remaining activity in each sample was then 
expressed as a percentage of the normal binding.
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5.2.5 Solubilised TSH Receptor Binding Kinetics.
The binding of bTSH tracer to Triton XI00 solubilised 
porcine receptors over time and temperature were studied.
All determinations were carried out in triplicate. Briefly 
aliquots of freshly thawed porcine receptor preparation were 
incubated with bTSH tracer (RSR, Cardiff, UK) for 15, 30, 45, 
60, 120, 180 AND 240 minutes AT 4°C, 25°C and 37°C according 
to the general methods described in 5.2.3.
Binding was expressed as a percentage of the total counts 
added.
5.2.6 Lectin Affinity Chromatography Qf Porcine TSH
Receptors♦
Lectins are saccharide binding proteins and glycoproteins. 
They bind mono' and oligosaccarides with great specificity 
through complementary sugar binding sites (Lotan & Nicolson, 
1979; Sharon, 1977). Because they generally contain at least 
two saccaride binding sites per molecule, their interaction 
with glycoproteins resembles that of antibodies.
Since the TSH receptor like most cell surface components 
is a glycoprotein, lectin affinity chromatography could be 
utilised as a purification tool. Elution of bound proteins 
from immobilised lectins is normally achieved under mild 
conditions , typically by displacement with simple sugars, 
thus helping keep the protein in an active form.
Previous studies have reported that bovine and human TSH 
receptors interact with conanavalin A, Wheat Germ agglutinin 
1 and Bandeiraea simplicifolia lectin 1 (Drummond et al.
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1982; Kress & Spiro, 1986; Taylor, 1987) .
In this series of experiments several common lectins were 
used in an attempt to purify the porcine TSH receptor.
4 Omg of the following lectins were coupled to amino 
activated glass beads (500A, lOOudiam, Clifmar Associates, 
Guildford) by the general procedures described in section 
2.2.9.
Concanavalin A (Sigma Chemicals)
Wheat Germ agglutinin 1 (Vector Labs, Sussex)
Bandeirea (Griffonia) Simplicifolia lectin 1 (Vector) 
Erythrina cristagalli lectin (Vector)
The beads were packed into small disposable columns 
(Biorad Laboratories) then were equilibrated at 4°C with 
lOmM HEPES buffer pH7.4, containing 5 0mM NaCl, 0.02% V/V 
Triton X100, O.OlmM CaCL2 and 0.02% W/V sodium azide.
5ml of Triton solubilised porcine thyroid membranes 
(prepared according to the methods 5.2.1) were applied to 
each column and allowed to interact for 30 minutes. After a 
wash step with equilibration buffer, elution of bound 
material was achieved with 0.1M methyl-a-D-galactoside (B 
Simplicifolia), 0.3M N-acetylglucosamine (Wheat Germ 
agglutinin), 0.5M methyl-a-D-mannoside (Concanavalin A) and 
0.2M lactose (E cristigalli) . 1ml fractions were collected 
and assayed for TSH binding activity (5.2.3) and total 
protein (B.C.A assay. Pierce Wariner Ltd, UK).
Non specific binding was assessed by elution with a high 
molarity non-specific sugar (sucrose).
For SDS-PAGE studies, repeat column elutions were carried
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outf the fractions collected were pooled and freeze dried.
5.2.7 TSH Affinity Chromatography.
Purification of the porcine thyrotropin receptor by TSH 
affinity chromatography has been previously reported by 
several groups (lida et al, 1983, 1987; Akamizu et al, 1988; 
Kress & Spiro, 198 6; Islam & Farid, 1985) and has permitted 
it's "characterisation" by polyacrylamide gel 
electrophoresis (PAGE). Elution conditions however, have 
tended to be harsh, severely reducing bioactivity.
In this study affinity purification was attempted under 
mild elution conditions as a preparative purification tool 
in obtaining active receptor.
2Omg (20IU) of bovine TSH were coupled to CNBr activated 
sepharose 4B (Pharmacia LKB) and were equilibrated at 4°C 
with lOmM HEPES buffer pH7.4, containing 0.02% V/V Triton 
X100, O.OlmM CaCl2 and 0.02% W/V sodium azide.
10ml of Triton solubilised porcine thyroid membranes were 
then applied and allowed to interact for 1 hour. Following a
wash stage , bound protein was eluted by means of several
buffers. These were;
50mM HEPES pH7.4 containing 500mM NaCl
50mM HEPES ph7.4 containing 1M NaCl
25mM Glycine pH4.0 
25mM Glycine pH3.0 
25mM glycine pH2.2
Fractions eluted with glycine were immediately desalted 
into lOmM Tris-HCl pH7.0 using a disposable PD10 column 
(Pharmacia LKB, Uppsala, Sweden).
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5.2.8 SDS-PAGE OF Porcine TSH Receptors.
Electrophoretic examination of the porcine TSH receptor
preparations was used to assess the purification 
methodologies. 5% and 7.5% discontinuous Tris slab gels were 
run according to the general methods described in 4.2.6. The 
subsequent gels were stained with coomassie blue and 
photographed.
Lectin purified thyroid membrane proteins were freeze 
dried before being dissolved into sample buffer.
5.2.9 Triton X1QQ Removal.
The presence of high levels of Triton XI00 have been 
reported to inhibit TSH binding to the receptor (Taylor, 
1987; Czarnocka et al, 1979).
It has also been reported that all detergents at 
concentrations equal or higher than their critical micelle 
concentration (CMC) prevent attachment of proteins to 
polystyrene microtitre plates (Gardas & Lewartowska, 1988) .
For these reasons the solubilised TSH receptor 
preparations were stripped of Triton X100 by the procedures 
of Holloway, 1973, before being assessed in the porcine 
radioreceptor assay.
Briefly (O.lg/ml preparation) SM-2 Biobeads (Biorad 
Laboratories) were added to the solubilised TSH receptor 
preparation.
After roller mixing at room temperature for 30 minutes the 
beads were separated and the preparation assessed for 
receptor binding activity (5.2.3).
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The stripped preparation was also assessed in the proposed 
ELISA formats. The loss of protein to the beads was assesed 
by the B.C.A assay (Pierce & Wariner Ltd).
The following conjugates were prepared for use in a 
competitive ELISA.
5.2.10 Preparation Of FITC Conjugated TSH.
1) 5mg (5IU) of bovine TSH (Sigma Chemicals) were desalted 
into 0.2M sodium bicarbonate pH9.0 using a disposable PD10 
column.
2) A 2mg/ml stock solution of fluorescein isothyiocynate 
isomer 1 (Sigma) (FITC) was prepared in bicarbonate pH9.0. 
0 .5ml of this stock solution were added to the protein 
solution and roller mixed overnight at 4°C wrapped in foil.
3) Separation of the conjugated protein from the free 
fluorochrome was achieved by passing the mixture through a 
PD10 column pre- equilibrated with PBS pH7.4.
4) The fluorochrome: protein ratio was determined by means 
of the following equation (Hudson & Hay, 1989), which takes 
account of FITC interference at 280nm.
F/P Ratio = 2.87 X ÂBS. 49,ShHLl.
ABS280nm - 0.35X ABS 495nm
5) The conjugate was then sterile filtered, aliquoted and 
stored at -20°C until required.
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5.2.11 Preparation Of Sheep Anti FITC Conjugated Alkaline
Phosphatase.
Sheep polyclonal 1701 15,3,89 (Guildhay Antisera Ltd) 
raised against Keyhole limpet haemocyanin-FITC conjugate 
underwent a 50% V/V ammonium sulphate cut followed by DEAE 
purification by standard procedures (Hudson & Hay, 1989).
The resultant protein eluate was further purified by gel 
filtration (S300 Sephacryl column 30 X 1cm) to separate the 
IgG peak. 5mg of the ’’purified" sheep anti-FITC polyclonal 
was then conjugated to alkaline phosphatase and HRPO by the 
methods previously described in sections 2.2.12 & 2.2.13.
5.2.12 Preparation Of TSH Alkaline Phosphatase Conjugates.
The first TSH-alkaline phosphatase conjugate was prepared
essentially as described by Miyai et al, 1976 using 
glutaraldehyde as the coupling agent. The procedure was as 
follows;
50ul(10mg/ml) alkaline phosphatase (Boehringer Mannheim, 
West Germany, Grade 1, 2500U/mg) were mixed with 400ul (2IU) 
bovine TSH ( Sigma) and 2 0 Oui of 1.25% glutaraldehyde 
solution prepared in PBS pH7.4. The solution was roller 
mixed at room temperature for 3 hours.
Unreacted groups remaining on the conjugate were "capped" 
by the addition of lOOul 0.2M glycine pH7.0. Following a 2 
hour incubation the conjugate was dialysed against 5 litres 
of PBS pH7.4 for 24 hours.
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The second alkaline phosphatase conjugate was prepared 
using the heterobifunctional reagent SMCC according to the 
general methods described in 2 .2 .12.
The conjugation ratio was modified to 2:1 (TSH : alkaline 
phosphatase) to account for the size disparity between the 
two proteins.
5.2.13 Preparation Q_£ TSH-Horse Radi sh P e r p x i d.£-S_£
Conjugates.
Five TSH-HRPO conjugates were prepared using a 
modification of the two step periodate reaction described by 
Beyzavi et al,1987 for labelling antibodies.
The following weight ratios were coupled according to the 
procedures previously described in 2.2.15;
1:2, 1:1, 2:1, 4:1, 8:1 (Enzyme: TSH).
5.2.14 Preparation Of TSH-Glucose Oxidase Conjugate.
Bovine TSH was coupled to glucose oxidase (GOD) according
to the methods of Nakane & Kawasi, 1974; Albert et al, 1978.
lOmg of GOD (EC 1.1.3.4 type Vll, Sigma) were dissolved in 
1ml of distilled water. 0 .1ml sodium periodate was added and 
allowed to react at room temperature for 30 minutes.
The activated enzyme was then dialysed against 4mM sodium 
acetate buffer pH4.4 at 4°C for 12 hours.
lOmg of bTSH were desalted into 0.1M sodium bicarbonate 
pH9.6 using a PD10 column and were subsequently combined 
with the activated enzyme.
The volume of the mixture was increased to 10ml with
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bicarbonate pH9.6 and allowed to react for 2 hours.
The reaction was terminated by the addition of 0.5ml 
ethanolamine buffer pH8 .0 (5% V/V ethanolamine + 0.05M
glycine). The resultant conjugate was dialysed against 5 
litres of PBS pH7.4, before finally being stored at 4°C 
until required.
All conjugates were purified by gel filtration to separate 
free ligand remaining in the conjugate mixture. Briefly, 
conjugates were applied to a 30 X 1.5cm Sephacryl S300 
column (Pharmacia LKB) which was pre equilibrated with PBS 
pH7.4. The absorbance at 2 8 Onm of the fraction were 
determined and the "protein" peaks pooled.
5.2.15 Development Of A Competitive ELISA For TSH Receptor
Autoantibodies.
The following section describes the various optimisation 
steps undertaken in the development of a possible 
competitive ELISA.
The proposed assay format depends on the competition 
between a TSH- enzyme conjugate label and sample 
(autoantibodies/ bTSH) for a limited number of TSH receptor 
binding sites on a coated microtitre plate. Initial 
optimisation experiments were undertaken in a buffer (Tris- 
HCl pH7.4 containing 5% W/V B.S.A) matrix.
Antigen Coating And Conjugate Dilution Studies.
Various Triton X100 solubilised TSH receptor preparations 
were serially diluted and coated (passively/ covalently) 
onto NUNC maxi sorb microtitre plates by the methods
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described in 5.2.16
The optimum coating concentration was determined for each 
preparation and conjugate (5.2.9-5.2.14). This was achieved 
by means of a simple displacement assay.
Briefly, lOOul of conjugate and buffer (with/without bTSH 
inhibit ,r) were added to the plate wells in duplicate at 
various concentrations and incubated for 1 hour at 37°C. 
Following a wash step the appropriate substrate was added 
and incubated for a further 30 minutes.
Any displacement of colour product by inhibit r observed 
in these initial studies then underwent further 
modifications, in an attempt to get a sensitive standard 
curve.
The effects of sample volume, dilution, conjugate volume, 
dilution, incubation time were all thoroughly investigated.
5.2.16Indirect ELISA For TSH Receptor Autoantibodies.
Anticren Preparation
Solubilised porcine receptor proteins were initially 
prepared by the methods described in 5.2.1. This crude 
preparation then underwent lectin affinity chromatography on 
a Bandeirea Simplicifolia column (5.2.5) followed by 
detergent removal on SM-2 Biobeads (5.2.9).
The resultant proteins were diluted to a concentration of 
20ug/ml in bicarbonate buffer pH9.6 . The protein level was 
determined by the B.C.A assay (Smith et al, 1985) .
200ul were applied to each well and incubated for 2 hours 
at 37°C. The plates were subsequently washed four times with
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TBS buffer and finally blocked with PBS containing 5% W/V 
lactose, 1%W/V B.S.A and 0.5% W/V casein for 30 minutes at 
room temperature.
Plates were inverted, allowed to air dry and were stored 
at 4°C until required.
Sample Preparation And Assay Protocol.
1 aliquot of human positive standard sera (10841) 
previously calibrated against the MRC LATS standard B 
(Henning Berlin GMBH TRAK assay) was serially diluted in TBS 
pH7.4. Patient samples and negative control (pooled normal 
human serum) were diluted 1 in 10 in TBS, before 20Oui were 
applied to the wells. The plate was incubated for 60 minutes 
at 37°C and then washed four times with TBS.
200ul of alkaline phosphatase conjugated affinity purified 
sheep anti human IgG (prepared according to the methods 
2.2.12) were applied to each well and incubated for 30 
minutes at 37°C.
Following a final wash stage, 200ul of PMP substrate were 
added and the colour allowed to develop for 30 minutes at 
37°C. The reaction was terminated by the addition of lOOul 
1.5M NaOH. The absorbance was read at 550nm on a titretek 
multiscan plus (ICN, FLOW). Sample LATS concentrations were 
determined from the constructed standard curve.
5.2.17Optimisât ion Qf. ELISA.
A series of experiments were performed to determine the 
optimum antigen coating concentration ,antibody 
concentration and incubation periods that would give the 
best antibody curve. A human serum with a known high MRC
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LATS activity was used as a positive control and pooled 
normal human sera as a negative.
Antigen Coating Studies.
Various TSH receptor preparations were examined as 
suitable coating materials in the ELISA. Triton XI0 0 
solubilised, detergent stripped, and affinity purified 
batches were all investigated.
Coating of the microtitre plates were performed at 4, 25 
and 37°C for 2 hours or (IShours) overnight. Passive binding 
was carried out at pH7.4, 9.0 and 9.6 in bicarbonate buffer. 
Covalent linkage experiments were also performed utilising 
NUNC covalink plates, glutaraldehyde, and poly -L-lysine 
(mw20,000). Plates were pretreated for 1 hour with various 
concentrations of the linkers in PBS pH7.4, prior to antigen 
coating.
The optimum concentration of receptor antigen was 
determined by incubating the previously calibrated positive 
and negative controls at constant dilution.
Both control sera were incubated in duplicate at a 1 in 10 
dilution for 60 minutes at 37°C. All subsequent assay steps 
were performed using the general assay protocol 5.2.16. 
Sample Incubation Time
The positive and negative control sera were assessed at a 
1 in 10 dilution over the following range of incubation 
times (15, 30, 60, 120, 180 minutes) according to the
general assay protocol(5.2.16).
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Blocking Studies.
The following blocking agents were examined with the aim 
of reducing heterophi.' lie antibody binding (NSB) ;
1% W/V B.S.A 
0.5% W/V Casein 
0.1M Glycine
5% V/V Normal donkey serum (Guildhay Antisera Ltd). 
Combination of the above.
400ul were applied to the microtitre plates for 60 minutes 
at 25°C.
5.2.invalidation Of The Proposed Method.
Specificity.
The specificity of the proposed ELISA was assessed by 
hormone displacement studies. bTSH, hTSH, HCG, insulin and 
FSH were spiked at various levels into the positive control 
serum. Displacement by TSH would suggest that the 
autoantibodies are only binding specifically to the 
receptor.
Imprecision.
To determine the intra assay imprecision, 3 positive 
samples were assessed 16 times. The day to day precision was 
assessed by analysing aliquots of 2 samples for 10 working 
days.
Detection Limit.
The MRC LATS standard B was serially diluted and measured 
in the ELISA. The last dilution which is distinguishable 
from the negative control (2 X S.D) was assumed to be the 
limit of detection.
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Method Comparison^
75 serum samples were analysed by the proposed ELISA and 
the existing radioreceptor assay (5.2.3) . The results 
obtained were correlated.
Interferences &_ Cross- Reactivity.
The cross reactivity of other autoimmune sera was examined 
in the proposed ELISA. Autoimmune sera for Tg, ICA, T4, DNA, 
insulin, TMA, gastric parietal cell and mitocWidria 
(collected by Patsey Prescott, St Lukes Hospital, Guildford) 
were all assessed in the assay according to standard 
methods.
Recovery.
10 normal patient sera were spiked with known MRC Lats 
activity and were assessed in the general ELISA protocol to 
determine recovery.
Stability Qf. Reagents.
The stability of the coated microtitre plates at 4, 25, 
and 37°C were assessed at 4 day intervals. The absorbance of 
the positive and negative controls were compared to freshly 
coated strips. The alkaline phosphatase conjugate is known 
to be stable ready diluted for at least 12 months at 4°C.
5.3RESULTS.
5.3.1 TSH Receptor RIA.
Tracer preparation and purification.
Bovine and human TSH tracers were prepared by iodination 
using the standard Chloromine T method. The iodinated TSH 
was purified by gel filtration on a Sephacryl S300 column. A 
typical elution profile is shown in Figure 5.1. The first
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peak represents aggregated material, the second iodinated TSH 
and the latter unincorporated iodine.
The iodinated TSH peak was pooled, receptor purified and 
then run through a further S300 column. An example of an 
elution profile is shown in Figure 5.2. Both peaks were 
found to be "active". The initial peak however, showed much 
lower background binding in the assay.
Human TSH tracer was found to bind in the assay, but could 
not be displaced.
Assay Curve Reproducibility.
A typical TSH radioreceptor assay curve is shown in Figure 
5.3. The intra assay reproducibility at 100 MRC LATS units 
was 5 .5% (n=10) and interassay variation was 8 .6% (n=10).
5.3.2 Porcine Receptor Stabilisation.
Several protease inhibitors were examined for their 
ability to reduce protein degradation of the TSH receptor. 
The data obtained is shown graphically in figure 5.4. Only 
PMSF and glycerol showed any inhibitory action, suggesting 
the loss of binding activity is not due to proteases.
5.3.3 TSH Binding Studies.
The binding of bTSH to Triton X100 solubilised receptors 
over time and temperature were studied. The results obtained 
are shown graphically in Figure 5.5.
The TSH tracer was found to rapidly bind (30 minutes) to 
the receptors and once bound was relatively stable.
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5.3.4 Purification Studies.
The solubilised receptor preparation underwent affinity 
chromatography on a number of immobilised lectins.
The receptor protein (TSH binding proteins) was found to 
bind specifically via it's glycosidic residue to 
concanavalin A, Bandeirea Simplicifolia and Wheat germ 
agglutinin. The elution profiles from these lectins are 
shown in Figures 5.6, 5.7 and 5.8.
Active receptor could not be eluted from the conanavalin A 
which is in general agreement with the work of Kress & 
Spiro,1986.
TSH affinity chromatography was found to bind all the 
receptor activity in the solubilised preparation but elution 
proved difficult.
Glycine pH4.0 containing 500mM NaCl was required to remove 
the majority of bound protein, which was subsequently found 
to have very low binding activity.
The column purified fractions from the TSH affinity 
column. Wheat germ affinity column and the B Simplicifolia 
column were subjected to SDS-PAGE.
The gel obtained was photographed and is shown in plate 
5.19.
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5.3.SDeteraent Removal.
The reduction of Triton XI00 in the receptor preparation 
from ,1% to 0.05%W/V helped increase zero binding in the TSH 
radioreceptor assay by 8% (n=6). The complete removal caused 
the total loss of binding activity.
The loss of protein during the extraction to the beads was 
deemed negligible (less than 2%) by B.C.A assay, when 25ml 
(4mg/ml) batches of thyroid membrane proteins were 
processed.
5.3.6 Development Of A Competitive ELISA For TSH Receptor
Autoantibodies.
TSH Conjugate Preparation And Assessment.
bTSH was successfully conjugated to alkaline phosphatase, 
HRPO, FITC and glucose oxidase by the methods previously 
described. All the conjugates were purified by gel filtration 
to remove aggregates and free reactants. The column profiles 
obtained are shown in figures 5.10, 5.11 and 5.12.
The pooled conjugates were then serially diluted and 
assessed for binding and displacement on a commercial TSH 
antibody coated plate (Guildhay Antisera Ltd).
Typical titres obtained were as follows;
Glucose oxidase 1 in 250
HRPO (4:1) 1 in 1000
Alkaline Phosphatase 1 in 500
FITC 1 in 10,000
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Optimisation Studies QjL ELISA.
Various thyroid membrane antigen coatings were studied 
with all the above conjugates over a range of dilutions. A 
small amount of displacement was achieved with all the 
conjugates except glucose oxidase. However, only significant 
displacement was obtained with the TSH-FITC anti FITC 
alkaline phosphatase amplification system.
This format was further optimised and assessed. The effect 
of pH, buffer concentration and saline were all examined. 
The results are presented graphically in Figure 5.13 and 
5.14. Saline below 250mM had little effect on the assay.
The final optimum buffer conditions were determined to be 
50mM Tris-HCl pH7.4 containing no saline (Figure 5.15). 
Hormone displacement studies showed the binding to be 
specific. The results are tabulated in Figure 5.16.
In a serum matrix, the TSH-FITC conjugate failed to 
displace significantly. Alteration of all assay parameters 
failed to eliminate this problem. The development of the 
proposed competitive ELISA was therefore terminated in 
favour of an indirect ELISA.
5.3.7Development Of An Indirect ELISA For TS.H Receptor.
Autoantibodies.
TSH receptor autoantibody dilution curves were obtained 
using serum positive for LATS activity. A typical standard 
curve is shown in Figure 5.17.
At a 1 in 10 dilution, 400lU/ml MRC LATS activity gave an 
absorbance at 55Onm of 1.6 with a negative of 0.12. This 
standard curve was obtained from the following optimisation
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studies.
Coating Of Thyroid Membrane Antigens.
Various solubilised TSH receptor preparations were 
assessed for their suitability as coating material in the 
proposed ELISA.
These experiments strongly suggested that preparations 
that had undergone affinity purification on immobilised B 
simplicifolia and which were detergent stripped, gave the 
best dilution curves. The optimum coating concentration was 
determined to be 20ug/ml (Figure 5.18).
Membrane preparations that were not affinity purified gave 
high binding in the ELISA, but little differentJaManbetween 
positive and negative controls.
The reduction of Triton XI0 0 helped increase the 
absorbance of the positive control serum.
Sample Incubation Times.
The optimum sample incubation time was determined to be 1 
hour at 37°C. After this time point, the differentiation 
between positive and negative controls was at it's greatest. 
Further incubation caused an increase in non specific 
binding (Figure 5.19).
Plate Blocking Studies.
Blocking the microtitre plates to reduce non specific 
binding was found to be crucial in obtaining a significant 
signal difference between positive and negative LATS serum.
A mixture of B.S.A, casein and lactose was observed to be 
the most efficient blocking agent.
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5.3.8 Performance Validation Of The Proposed ELISA. 
Imprecision.
The intra and inter assay variation of the indirect ELISA 
were assessed at 3 levels. The results are shown in Table 
5.20 & 5.21.
Cross Reactivity Studies.
No significant cross reactivity was observed in the ELISA 
with autoimmune sera to ICA, mitochondria, insulin, gastric 
parietal cell, DNA, TMA and T4. Several thyroglobulin 
autoantibody positive sera were positive for LATS activity 
by ELISA. This is probably due to the presence of receptor 
antibodies in the patient sample; since sheep polyclonal 
antisera raised against thyroglobulin failed to interfere. 
Detection Limit.
The minimum LATS activity detectable was determined to be 
5mU/ml.
Specificity.
The specificity of autoantibody binding was assessed by 
hormone displacement studies. Only bTSH was capable to 
displace the positive LATS antiserum control (Figure 5.22). 
High levels of HCG, FSH, and insulin failed to cause 
significant displacement.
Recovery.
Recovery of LATS activity in spiked samples were in the 
range 93-100% (mean=96%).
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Method Comparison.
75 thyroid autoimmune serum samples were analysed by the 
proposed ELISA and the radioreceptor assay (5.2.1) . The data 
obtained is shown in Figure 5.23. The correlation was 
determined to be
y = 25.02 + 1.149X r = 0.84
These Lemming regression data were calculated by the 
methods of Cornbleet and Gochman, 1979.
The normal range of the assay was determined to be below 
20U/L (n= 25) .
Stability Qf. Assay Reagents.
The thyroid antigen coated plates were found to be stable 
at 4°C for at least 3 months and 1 month at room 
temperature. The enzyme conjugate is stable ready diluted 
for at least 1 year at 4°C.
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Figure 5 .16 The Effect Q£ Potentially gX-O^ -S ReastiYÆ 
Hormones In The Competitive TSH Receptor Autoantibofly Ell SA,^
HORMONE CONCENTRATION & DISPLACEMENT,
Control NA 100
bTSH 5mU/ML 93
bTSH 0.5mU/ml 14
HCG 0.5 X105mU/ml 98
HCG 2.0 X105mU/ml 84
LH 100mU/ml 100
Insulin 2,000ug/ml 101
Thyroglobulin Smg/ml 98
NA = not applicable.
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Table 2Û Intra Assay Precision Q£ Xh& Indirect ISfî ReceptOC
Autoantibodv ELISÂ*
MEC lats activity sn 221&1 TERMS (HI
ü/L
305 11.3 1.37 16
102 3.87 3.8 16
39 2.06 5.2 16
Where CV = 
SD =
Coefficient of variation 
Standard deviation.
Table 5.21 Between Day Precision Of The
Receotor Autoantibodv ELISA.
MRC LATS B SD CVf%)
SLZL
Indirect TSfl 
TERMS(n)
304 17.9 5.9 10
40 3.44 8.6 10
Where CV = 
SD =
Coefficient of variation 
Standard deviation
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Table 5.22 ihe Effect Q£ Potentially gross Reactive Hormones 
In Xhs. Proposed Indirect ELISZl,
hormone CONCENTRATION ABSSSQnm DISPLACEMENT
±YE CONTROL ill
Control NA 1.65 100
bTSH SmU/ml 1.43 83.4
bTSH 0.5mU/ML 1.43 13.3
Insulin 2 , OOOug/ml 1.64 0.61
LH 100mU/ml 1.66 -0.61
HCG 0.5 x 105mU/ml 1.62 1.82
HCG 2.0 x 105mU/ml 1.58 4.24
NA = Not applicable
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5.4 DiS-CnSSIfllL.
The above study describes the formulation and validation 
of a radioreceptor assay, and an indirect ELISA for the 
measurement of TSH receptor autoantibodies.
The initial experiments concentrated on the partial 
purification and stabilisation of the porcine receptor, 
since the use of mixed or crude antigens in an ELISA format 
can present significant problems in the sensitivity and 
specificity of the procedure. This is probably due to the 
competition between proteins for absorption sites on the 
microtitre plate.
It has previously been reported that components present at 
1% or less in a mixture are essentially unde'ferfetie, unless 
excessive amounts of conjugate are used (Kenny & Dunsmoor, 
1983).
Since the TSH receptor is poorly expressed oh human 
thyroid membranes (Furmaniak, 1990), purification was deemed 
necessary for the ELISA development.
Purification studies of the porcine receptor using 
immobilised lectin affinity columns revealed useful 
information about it's carbohydrate moiety. The binding to 
concanavalin A, B Simplicifolia and Wheat Germ agglutinin 
indicated the presence of N-linked oligosaccarides, a-D- 
galactosyl and sialyl sugar residues respectively.
" Active" TSH receptor proteins could be eluted from all 
the immobilised lectins except Concanavalin A. This is in 
general agreement with Kress and Spiro, 1986, but contrary 
to the work of Drummond et al, 1983.
SDS-PAGE analysis of the affinity purified membrane
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preparations revealed the presence of several protein bands.
On the TSH affinity column the following bands were 
observed; llOKda, 90Kda, 70Kda and SOKda.
From the Wheat Germ agglutinin column the following bands 
were detected, 210Kda, 180Kda, lOOKda 70Kda and SOKda.
The B simpilicfolia column revealed the presence of many 
protein bands. The strongest visible bands included the 
following apparent molecular weights, llOKda, SOKda, 70Kda 
and SOKda. The presence of a 5 0, 00 OMW protein in all 
preparations is in accordance with the cloned and partially 
purified TSH receptor A subunit molecular weight (Libert et 
al,1989; Furmaniak & Rees Smith, 1990).
This is also in general agreement with the work of Kress 
& Spiro, 1986 on the bovine receptor and Drummond et al, 
1983 on the human receptor.
Stabilisation studies using protease inhibitors within the 
receptor preparation proved ineffective. Only the presence 
of 20% V/V glycerol had any significant protective 
influence. This strongly suggests that the labile nature of 
the TSH receptor is not due to protease degradation. 
Considering that the porcine receptor preparation can be 
lyophilised and reconstituted without significant loss
of activity tends to suggest that the solubilised receptor 
is not just falling apart in it's new environment. Maybe 
other degrading enzymes present in the membrane preparation 
such as glycosidases are involved in the loss of binding 
activity. Karsenty et al, 1986 has previously shown the 
importance of carbohydrate moiety in TSH binding to the TSH 
receptor * ,
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Initial ELISA development was directed towards a 
competitive system using enzyme labelled TSH. The 
displacement of the TSH-enzyme conjugate from the 
immobilised receptor preparation however, proved difficult 
in a serum matrix. This may have been due to a 
conformational change within the receptor whilst being 
immobilised, or alternatively the possible deformation of 
the TSH molecule through conjugation.
Alteration of all the assay parameters (serum dilution, 
antigen coating concentration, conjugation methodology etc) 
failed to eliminate this problem, therefore further 
developmental work was directed towards an indirect ELISA.
The fully optimised indirect ELISA for TSH receptor 
autoantibodies could be performed in 90 minutes, was cheap, 
robust and appeared suitable for large scale screening of 
patient sera.
The proposed assay was observed to have good recovery (96- 
100%) of "spiked" MRC LATS B activity, good precision and no 
significant cross reactivity with other common known 
autoantibodies( TPO, ICA,Tg, GPC).
Hormone displacement studies supported the specificity of 
the assay. Only very high levels of HCG could inhibit 
binding . This level of cross reactivity with the TSH 
receptor has previously been reported by Hoermann et al, 
1991.
Comparison of the proposed ELISA with the radioreceptor 
assay gave a poor Deming correlation coefficient (r = 0.84 
Cornbleet & Gochman, 1979). This was probably due to the 
presence of other unidentified autoantigens present in the
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ELISA antigen coat.
Alternatively, the receptor having been immobilised to the
]=>£
microtitre plate may no longer ^ recognised by the 
autoantibodies. This could be due to antigen deformation or 
auto-epitopes being concealed. These problems might be 
overcome by the use of pure receptor antigen or recombinant 
material.
The previous TSH receptor ELISA reported by Chang & Liaw, 
1988 had no correlation with the cAMP bioassay or the 
radioreceptor assay. This was almost certainly due to the 
crude nature of their receptor preparation which would be 
grossly contaminated with both Tg and TPO.
The Dot immunobinding assay on nitrocellulose paper (Bako 
et al, 1987) reportedly correlated well with the existing 
radioreceptor assay. However, close scrutiny of the method 
revealed the coating preparation also contained Tg.
The ideal assay system would be where the TSH receptor 
was "held" in an environment similar to it's native state, 
perhaps within a normal plasma membrane not expressing other 
antigens. This could theoretically be achieved by cloning 
the receptor into mammalian expression lines(Ludgate, 1990).
In conclusion, this study describes the development and 
validation of a TSH receptor autoantibody assay which is 
cheap, robust and relatively specific. It could therefore be 
useful in the large scale screening of thyroid patient sera. 
Any positive samples could always be confirmed by 
radioreceptor assay if necessary.
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CHAPTER SIX
OVERALL DISCUSSION AND CONCLUSIONS.
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Production Of thyroid Derived Cell Lines.
An understanding of the molecular mechanisms underlying 
cell growth, differentiation and function of human cells is 
one of the most challenging aspects of modern cell biology 
today. The success of recent investigations in this area 
have been greatly influenced by the availability of 
experimental in-vitro systems in which the cellular 
environment closely resembles that encountered by cells in- 
vivo (Bidey et al, 1988).
However, for any particular cell type, the successful 
implementation of such "models" is dependent upon the 
isolation of long term stable cell lines which are 
phenotypically similar to the cells present within the 
parental tissue.
In the absence of stable thyrocyte lines, early studies on 
thyroid follicular cell function depended upon cells
being isolated directly from tissue and maintained in 
primary culture.
Whilst in many respects these primary cultures show many 
characteristics of the original tissue, they are fraught 
with problems (reviewed in section 1.3.1).
To overcome these problems, various laboratories have 
attempted with some success to immortalise the thyrocyte and 
produce stable cell lines.
These cell models, such as FRTL-5 (Ambesi-Impiomabato et 
al, 19 8 0) and WRT (Brandi et al, 1987) cell lines have 
yielded a great deal of information about general thyroid 
autoimmunity and biochemistry. Yet, they suffer from one 
major disadvantage in that they are of animal origin.
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The production of stable human thyrocyte lines has proven 
more difficult. This is because they tend to be refractory 
to establishment (Linder & Marshall, 1990) .
Human cells when passaged in vitro reach a fixed number of 
cells, a stage of no proliferation in which cell division 
ceases. This is sometimes referred to as cellular senescence 
(Shay et al, 1991; Linder & Marshall, 1990). To overcome 
this problem various groups have utilised hybridoma 
technology (Karsenty et al, 1986; Martin et al, 1988) or 
have employed DNA viruses, for example SV40 (Lemoine et al, 
1989; Eggo et al, 1990; Davies et al, 1989) in an effort to 
override the cellular programme of ag<0 fn^ ~
In the present study, human heterohybridoma technology was 
employed in an endeavour to produce novel human thyrocyte 
lines. Second (mouse X human X human) and third (mouse X 
human X human X human) generation HAT sensitive 
heterohybridoma cell lines were successfully fused with 
primary human thyrocytes to initially produce 140 novel 
lines. Following cloning, expansion and continuous culture 
for 6 months, 70 stable cell lines (termed HTH) were 
obtained. These stable lines were only derived from the 
third generation fusion partner HFP3.
Karyotypic analysis of the fusion partners revealed that 
HFP2A contained 40 and 80 chromosomes suggesting that the 
"construct" line may have reverted back it's murine origin. 
This may help to explain the apparent instability in the 
derived fusion lines.
66 of the stable cell lines had classical hybridoma 
morphology, although were visually more granular than the
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parental fusion partner HFP3. 4 very fragile, slow growing 
cell lines were also generated with fibroblastic 
characteristics.
Preliminary screening of all the fusion lines revealed 
several secreting thyroglobulin. These lines however, proved 
unstable and eventually ceased to proliferate, suggesting 
possible chromosome instability. Further screening for 
common thyroid antigen expression all proved futile.
Using a specific human IgG ELISA several immortalised 
antibody secreting lymphocytes were identified. These lines 
were cloned, characterised and grown in continuous culture 
for 6 months without loss of secretion
Karyotypic analysis of several selected HTH cell lines 
confirmed their human origin.
Interestingly the human antibody secreting lines (HTH37, 
15) appeared to have a "normal" human karyotype with no 
obvious presence of murine DNA. This is in broad agreement 
with the work of De Silva et al, 1991 using the ancestral 
first generation heterohybridoma fusion partner HMY. This 
maybe due to the presence of a latent DNA virus present in 
the fusion line imparting immortalisation, or more likely, 
murine DNA being translocated onto the human chromosomes.
The fibroblastic lines obtained (HTH57, 60) revealed a
mixed karyotype typical of heterohybrid cells (Tan et al, 
1984; Sugiyama et al, 1991).
These results suggest that the thyrocyte DNA although 
being incorporated, is not being expressed in the hybrid 
cells. This problem was also observed by Martin et al, 1988 
with the generation of a thyrocyte-T cell hybridoma.
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Considering that the immortalised human lymphocytes present 
the thyroid were stable and secreted antibody, the problem 
suggests a possible incompatibility of the fusion line 
with the primary thyrocytes.
Therefore, in summary, the fusion of human epithelial 
thyrocytes with the heterohybridoma fusion partners enabled 
the production of 70 novel humanised cell lines which had 
three basic phenotypes. These were;
1)Immortalised thyroid infiltrating lymphocytes.
2) Mixed karyotype hybridomas, lymphocytic in nature.
3) Fibroblastic cells.
Only the fibroblastic lines appeared to show any thyrocyte 
characteristics. However, their complete lack of common 
thyroid antigen expression made them unsuitable as human 
thyrocyte cell "models".
Development Of An Assay For TSH Receptor Autoantibodies.
The initial aim of this thesis was to construct a human 
thyrocyte line which would express the TSH receptor. This 
would have enabled a continual source of human receptor 
protein ideal for assay development studies. Since no TSH 
expression cell line was obtained (chapter 3,4), ELISA 
development proceded using primary porcine tissue.
Existing assay systems for TSH receptor antibodies have 
tended to be time consuming, expensive and unreliable. They 
also have major reagent stability problems, making them 
unsuitable for large scale screening of patient sera.
To overcome these problems the possibility of developing an 
ELISA assay was investigated. Initial experimental studies
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concentrated on the purification and stabilisation of the 
solubilised porcine TSH receptor from the membrane 
preparation.
This purification of the TSH receptor was deemed necessary 
because of it's low expression on the thyrocyte membranes 
(Furmaniak, 1990). Previous reports have shown that the use 
of crude antigen coating preparations in ELISA can present 
significant problems in the sensitivity and specificity of 
the technique (Kenny & Dunsmoor, 1983) .
The existing radioreceptor assay (Southgate et al, 1984) 
was used as a screening tool to assess the purification 
strategies. The partially purified preparations were then 
evaluated in a competitive ELISA arrangement.
This proposed assay system depended upon enzyme labelled 
TSH conjugate competing with autoantibody for a limited 
number of immobilised receptor sites. Partial purification 
of the receptor was achieved using the combination of lectin 
(B Simplicifolia 1) and TSH affinity chromatography. The 
reduction of Triton XI00 within the preparation was also 
considered necessary to increase specific binding activity. 
The complete removal of detergent was observed to eliminate 
all binding "activity".
This ELISA format was eventually dropped in favour of an 
indirect approach as a result of serum matrix interferences, 
which severely reduced conjugate displacement.
The proposed indirect ELISA involved the immobilisation of 
partially purified porcine TSH receptor proteins on to 
microtiter plates. Sample autoantibodies were then allowed 
to bind for 30 minutes. These were then detected by means of
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a sheep anti human alkaline phosphatase conjugate. The amount 
of binding was converted into MRC LATS B units by means of a 
constructed standard curve.
The proposed assay could be performed in 90 minutes, was 
cheap, robust and was suitable for the large scale screening 
of autoimmune patient serum. The stability of the assay was 
found to be in excess of 3 months. The technique showed good 
intra and inter assay precision and had no significant cross 
reactivity with common autoantibodies. Method comparison 
with the existing radioreceptor assay gave a correlation or 
r= 0.84. It may therefore be a useful tool for the batch 
screening of autoimmune patient serum. Any positive samples 
could always be confirmed by the radioreceptor assay if 
necessary.
A previous ELISA for the detection of TSH receptor 
autoantibodies described by Chang & Liaw, 1988 had no 
correlation with either the cell bioassay, or the 
radioreceptor assay. This was almost certainly due to the 
crude nature of the antigen coating material which would 
have been grossly contaminated with thyroglobulin and 
thyroid peroxidase.
In terms of future work, the proposed ELISA could be 
improved in a manner of ways. The use of pure antigen, 
possibly recombinant (Filetti et al, 19 90; Ludgate et al, 
19 9 0) would help specificity. Determining better 
immobilisation procedures that would keep the immobilised 
receptor protein in conditions resembling it's native state, 
would also help.
200
Future Work.
This study has shown the possibility of using 
heterohybridoma technology as a means of overriding human 
cellular senescence. Further work is necessary however, in 
understanding how expression in these constructed hybrid 
lines could be achieved. Studies into the possibility of 
activating the silent DNA, perhaps by means of hormones and 
growth factors, such as interferon or IL-2 could be 
investigated.
The generation of human thyroid derived fusion partner 
could also be undertaken by treatment of one of the HTH 
lines with azcuguanine. These lines being "closer" to the 
primary tissue in nature may help expression in the next 
thyroid fusion.
It would also be extremely useful to establish which human 
and murine chromosomes have been retained in the HTH and 
fusion partner lines. This could be achieved using 
chromosome specific DNA probes which are now commercially 
available (Gibco, Paisley, Scotland). This may allow a 
greater understanding of how this immortalisation process 
occurs.
Undertaking a thyroid fusion in media containing human 
serum rather than foetal calf serum may also be 
advantageous.It has previously been reported that serum from 
the same species can help stabilise the resultant constructs 
(Lang & Bruderer, 1990; Watts et al,1990).
The heterohybridoma fusion partner HFP3 has been observed 
to immortalise human thyroid infiltrating lymphocytes and
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produce long term stable lines. It could therefore be used 
as a tool in the study of autoantibodies. Enabling the 
polyclonal autoantibody response to be "dissected” (Isenburg 
et al, 1984) .
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